<?xml version="1.0" encoding="UTF-8"?>
<svg height="870.031005859375" width="672.0029907226562" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <path d=" M 0.05999799817800522 826.072021484375 L 22.619997024536133 826.072021484375 L 22.619997024536133 826.35546875 L 0.05999799817800522 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 837.4110107421875 L 33.959449768066406 837.4110107421875 L 33.959449768066406 860.031005859375 L 33.67599868774414 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 837.4110107421875 L 628.2703857421875 837.4110107421875 L 628.2703857421875 860.031005859375 L 627.9869995117188 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 826.072021484375 L 662.0029907226562 826.072021484375 L 662.0029907226562 826.35546875 L 639.3259887695312 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 33.731998443603516 L 662.0029907226562 33.731998443603516 L 662.0029907226562 34.015480041503906 L 639.3259887695312 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 0.0 L 628.2703857421875 0.0 L 628.2703857421875 22.677000045776367 L 627.9869995117188 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 0.0 L 33.959449768066406 0.0 L 33.959449768066406 22.677000045776367 L 33.67599868774414 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 0.05999799817800522 33.731998443603516 L 22.619997024536133 33.731998443603516 L 22.619997024536133 34.015480041503906 L 0.05999799817800522 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="85.039,88.958,93.441,97.359,100.811,103.23200000000001,106.412,111.828,115.746,120.229,124.713,128.631,131.052,134.97,139.919,147.29,151.773,156.722,159.872,162.293,165.745,168.943,172.395,177.345,182.294,189.198,194.14700000000002,197.289,200.177,205.126,208.287,213.237,218.186,225.09,230.04,233.492,237.41,241.893,246.843,249.263,253.747,256.634,260.552,263.732,266.619,271.568,275.486,278.698,282.616,287.566,292.515,295.967,299.885,303.337,306.789,309.21,314.16,319.10900000000004,322.293,327.243" y="39.74800000000005" svg_rhmargin="330.13" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">eyes. Bevacizumab is shown to downregulate the expression of</text>
  <text x="85.039,89.989,93.907,97.359,101.842,105.76,111.855,116.338,119.79,124.739,131.644,134.531,139.48000000000002,145.586,148.473,152.956,156.875,159.762,164.711,168.163,170.584,176.653,181.136,187.198,192.147,197.097,199.518,204.001,208.95,212.868,217.818,220.705,223.126,228.075,231.993,238.107,240.994,245.943,249.395,255.511,260.461,263.913,268.862,276.232,281.182,284.069,286.49,291.439,295.922,301.998,305.916,310.866,314.318,319.267,323.185,327.668" y="50.690000000000055" svg_rhmargin="330.089" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">nerve growth factor, a polypeptide for promoting corneal</text>
  <text x="85.039,88.958,93.907,96.328,99.215,104.165,108.083,110.504,112.925,117.874,125.244,129.485,134.435,137.887,142.836,145.257,147.678,150.565,154.483,157.935,162.419,165.306,167.727,172.676,177.625,180.046,184.362,189.777,192.198,197.148,201.066,206.015,210.499,215.448,219.366,223.592,228.541,231.428,235.668,242.106,247.521,254.425,259.374,263.56,267.479,272.428,277.377,279.798,284.747,289.015,292.467,296.385,301.334,306.284,310.202,314.12,318.324,321.211,326.16" y="61.63099999999997" svg_rhmargin="330.078" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">epithelium proliferation. Blockade of VEGF could reduce the</text>
  <text x="85.039,89.523,92.975,97.924,104.828,107.715,112.664,115.312,119.795,124.745,129.69400000000002,132.32,135.772,139.69,144.173,148.091,153.041,156.959,160.411,164.894,167.781,170.202,175.152,180.101,182.775,187.724,190.611,193.263,197.181,202.13,204.551,207.438,212.388,215.84,219.758,224.70700000000002,227.391,232.34,236.259,241.208,244.66,249.61,254.559,258.011,260.669,265.618,270.101,272.744,277.694,282.643,291.609,294.23,298.714,303.663,308.612,311.238,316.187,321.137" y="72.62900000000002" svg_rhmargin="330.103" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">growth and regeneration of cultured neurons by 17% and 23%</text>
  <text x="85.039,87.46,92.40899999999999,94.167,97.619,102.102,104.989,108.441" y="83.57100000000003" svg_rhmargin="110.862" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">in rats.</text>
  <text svg_rhmargin="122.648" x="110.891,113.057,116.77,120.483,122.64800000000001" y="83.572" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[36] </text>
  <text x="124.384,131.853,136.803,143.707,147.625,152.108,156.026,159.478,161.899,163.671,168.154,171.606,173.365,177.284,182.233" y="83.572" svg_rhmargin="187.182" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">However, as con</text>
  <text x="187.2" y="83.572" svg_rhmargin="192.149" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬂ</text>
  <text x="192.133,194.554,198.472,201.359,203.78,208.729,213.21200000000002,214.98,218.898,223.381,225.802,230.751,234.67,239.619,243.537,247.456,249.87699999999998,251.659,256.608,260.527,265.01,269.493,273.411,275.832,279.75,284.7,292.07,296.553,301.502,303.248,308.197,310.618,315.567,317.307,322.256,327.206" y="83.572" svg_rhmargin="330.093" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">icting evidence, bevacizumab did not</text>
  <text x="85.039,89.522,92.409,95.297,99.215,103.133,106.02,108.453,111.34,116.289,120.20700000000001,122.569,127.519,130.971,135.92,138.341,140.762,143.649,147.567,151.019,155.503,158.39,160.811,165.76,170.709,173.138,178.087,180.974,183.342,187.26,192.21,194.631,197.518,202.467,205.919,209.837,214.786,217.186,222.136,227.085,234.455,238.939,243.888,246.268,250.187,255.136,258.588,263.538,267.456,271.939,274.36,276.768,280.687,285.636,288.057,290.944,295.893,299.812,302.233,304.653,309.137,311.558,313.958,317.876,321.794,324.215,326.636" y="94.51300000000003" svg_rhmargin="330.088" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">affect the proliferation of cultured human corneal epithelial cells</text>
  <text x="85.039,89.522,94.472,99.42099999999999,103.747,110.651,115.135,118.587,122.909,126.827,131.311,135.229,140.17800000000003,144.509,149.458,154.408,157.86,161.778,165.23,169.713,173.632,178.58100000000002,182.889,185.776,190.72500000000002,195.022,199.971,203.423,208.372,215.743,220.692,223.579,227.497,231.87,235.789,240.738,244.19,249.14,253.058,257.541,259.962,264.241,268.16,273.109,275.53,278.417,283.367,287.285,289.706,292.127,296.61,299.031,303.415,310.319,315.269,320.218,325.167" y="105.51099999999997" svg_rhmargin="330.116" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">and was even observed to promote corneal epithelial wound</text>
  <text x="85.039,89.989,93.907,98.39,100.811,103.232,108.181,112.664" y="116.45299999999997" svg_rhmargin="115.085" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">healing.</text>
  <text x="93.997,100.434,107.805,112.754,117.703,122.186,127.105,129.992,134.941,138.859,143.716,146.136,151.086,155.004,157.425,162.374,167.324,171.242,176.191,181.132,184.584,187.471,192.421,197.37,199.791,203.709,207.161,209.582,214.466,219.415,224.365,226.786,231.269,236.179,241.12800000000001,245.987,249.439,252.326,257.276,262.225,264.646,268.564,272.016,276.94,280.392,284.311,289.26,294.21,297.662,300.549,304.467,309.416,314.357,319.306,323.224" y="127.39499999999998" svg_rhmargin="330.128" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Among the included studies, only 3 studies reported new</text>
  <text x="85.039,88.957,93.907,97.359,102.308,106.227,110.71,113.131,114.972,119.922,123.84,126.727,130.645,134.564,137.451,139.35,144.299,147.751,149.611,154.56,156.981,160.899,164.818,168.27,170.133,174.051,178.534,182.453,187.402,190.289,193.74099999999999,195.587,200.071,205.02,209.96900000000002,211.801,214.688,219.638,223.556,225.408,227.828,232.778,236.696,239.117,244.066,247.985,252.934,256.852,260.77,262.654,266.106,270.589,275.538,280.021,283.94,288.889,290.773,295.722,304.688,306.533,309.42,314.369,316.227,321.177" y="138.39300000000003" svg_rhmargin="330.143" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">corneal defect or ulcer events and the incidence ranged 3% to 8%</text>
  <text x="85.039,91.943,94.364,97.251,102.201,107.15,112.099,114.986,117.353,121.836,124.156,127.608,130.029,134.513,139.462" y="149.33399999999995" svg_rhmargin="141.883" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">without a signi</text>
  <text x="141.903" y="149.33399999999995" svg_rhmargin="146.852" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="146.835,150.753,155.236,160.186,163.073,165.429,170.379,172.8,175.687,178.574,182.492,185.944,189.862,194.812,198.73,202.648,204.999,208.918,213.867,221.237,226.187,230.67,234.122,238.04,242.989,245.363,252.267,254.688,257.575,262.524,264.865,268.783,273.732,278.682,281.569,285.021,289.97,292.391,294.74,299.224,302.676,307.625,312.574,317.524,319.945,322.292,325.179" y="149.33399999999995" svg_rhmargin="330.128" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cant difference compared with control group. In</text>
  <text x="85.039,89.522,94.472,99.421,102.308,107.258,111.176,114.628,116.956,120.409,124.327,126.748,130.666,135.149,139.632,144.582,147.469,149.837,153.755,158.238,161.69,165.608,167.921,171.373,175.291,178.743,181.164,185.082,188.534,190.95499999999998,193.319,195.74,198.627,200.972,207.877,212.36,215.812,218.15,223.1,228.049,230.47,235.419,238.306,242.225,247.174,249.557,254.507,259.456,262.343,264.637,267.524,272.473,276.957,279.844,282.211,285.663,290.612,295.562,300.511,303.398,307.881,312.831,316.749,321.698,326.648" y="160.27599999999995" svg_rhmargin="330.1" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">another relevant case series, it was pointed out that spontaneous</text>
  <text x="85.039,88.957,93.907,97.359,102.308,106.227,110.71,113.131,115.369,119.287,124.236,126.657,129.544,134.494,138.412,140.833,143.254,147.737,150.158,152.388,157.337,161.255,164.143,168.061,171.979,174.866,178.318,180.507,187.877,192.36,196.84300000000002,199.045,203.528,205.949,209.401,214.35000000000002,216.562,221.512,225.43,227.617,232.1,234.307,239.256,244.205,247.092,251.011,255.96,258.847,261.268,265.751,268.17199999999997,270.418,274.337,279.286,286.656,291.606,294.027,296.448,300.366,304.849,307.736,310.157,315.106,320.055,322.29,327.24" y="171.21699999999998" svg_rhmargin="330.127" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">corneal epithelial defects may also be a potential complication of</text>
  <text x="85.039,89.522,94.472,97.359,99.78,102.667,109.105,114.52,121.424,126.373,132.319,136.802,141.286,145.204,150.153,153.04,158.908,163.391,168.341,175.711,178.132,183.081,185.502,188.954,191.841,195.293,199.776,202.664,205.084,210.034,214.983,220.928,223.815,228.764,234.647,238.566,243.049,246.967,250.419,256.304,263.208,265.629,268.516,273.46500000000003,279.377,283.86,289.752,294.702,297.123,300.575,303.462,308.411,311.863,316.346,322.293,327.242" y="182.21500000000003" svg_rhmargin="330.129" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-VEGF agent administration to eyes with a history of</text>
  <text x="85.039,89.989,93.907,97.359,101.842,104.729,109.679,114.628,117.049,121.532,124.984,127.871,132.354,134.775,138.158,145.062,149.545,154.494,157.887,161.805,164.692,168.091,172.574" y="193.15700000000004" svg_rhmargin="174.995" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">keratoplasty. Gan et al</text>
  <text svg_rhmargin="186.767" x="175.011,177.177,180.89,184.602,186.767" y="193.159" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[37] </text>
  <text x="190.148,193.6,197.518,202.468,207.417,210.869,213.756,217.675,222.62400000000002,226.034,228.921,233.87,238.354,241.241,244.629,249.578,252.963,257.913,260.8,264.188,269.137,272.465,276.383,280.866,284.785,288.237,291.627,296.576,300.495,304.978,308.896,311.317,316.266,321.216,325.134" y="193.159" svg_rhmargin="330.083" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">reported that 4 of 5 eyes developed</text>
  <text x="85.039,89.988,93.906,97.358,100.81,103.231,106.683,109.571,113.489,118.438,121.325,124.325,129.275,132.727,135.664,139.116,143.035,146.953,151.902,155.354,158.806,162.725,167.674,170.561,173.533,177.452,182.401,184.822,187.709,192.659,196.577,198.998,201.419,205.902,208.32299999999998,211.29,216.239,220.157,223.044,226.963,230.881,233.768,237.22,240.202,244.686,247.573,250.46,254.378,257.83,260.838,263.725,267.177,271.096,275.579,278.466,285.836,289.755,294.704,297.591,300.579,307.483,309.904,312.791,317.74,320.704,325.188" y="204.101" svg_rhmargin="330.137" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">persistent or recurrent epithelial defects after treatment with an</text>
  <text x="85.039,89.522,94.471,97.358,99.779,102.666,109.104,114.52,121.424,126.373,130.165,134.648,139.132,143.05,147.999,150.886,154.656,157.077,162.026,165.768,170.717,175.2,178.087,180.508,184.427,189.376,192.263,195.715,199.499,206.403,208.824,211.711,216.66000000000003,220.418,224.901,228.639,233.588,236.009,239.461,242.348,247.297,250.749,255.232,259.025,263.975,266.862,270.59,275.539,279.458,282.91,287.393,290.28,295.229,300.179,302.6,307.083,310.535,313.422,317.90500000000003,321.725,326.674" y="215.09900000000005" svg_rhmargin="330.126" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-VEGF agent in patients with a history of keratoplasty or</text>
  <text x="85.039,87.46,89.881,97.251,102.2,106.683,109.10400000000001,111.57,114.457,117.909,122.392,127.342,130.794,135.743,138.164,142.647,147.597,150.484,154.967,157.854,160.275,165.224,170.174,172.595,175.064,177.951,180.838,183.341,190.245,194.728,198.18,200.631,204.083,209.033,213.516,217.999,221.917,225.369,228.257,232.175,237.12400000000002,239.578,242.465,247.415,251.898,254.785,257.266,260.153,265.103,269.021,271.439,275.922,280.872,285.821,289.739,293.191,295.612,300.095,304.014,308.963,312.881,316.333,319.785,322.291,327.24" y="226.03999999999996" svg_rhmargin="330.127" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">limbal transplantation. It was suggested that the adhesiveness of</text>
  <text x="85.039,87.926,92.875,96.793,98.702,103.651,107.569,114.473,116.389,120.308,125.257,128.709,133.659,137.577,142.06,144.481,146.435,150.354,155.303,157.724,160.611,165.561,169.479,171.9,174.321,179.27,186.64000000000001,188.557,191.445,196.394,198.308,201.195,206.145,210.06300000000002,212.028,216.977,221.926,226.876,230.794,234.246,236.667,241.15,243.571,248.52,253.00300000000001,254.886,258.804,263.753,266.64,270.092,274.576,278.494,282.412,284.833,287.254,292.203,294.624,299.107,302.559,304.546,311.917,316.4,319.287,322.739,325.16" y="236.98199999999997" svg_rhmargin="330.109" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">the new corneal epithelium to the underlying extracellular matrix</text>
  <text x="85.039,92.409,94.83,99.313,104.262,107.149,110.55,115.499,119.982,124.465,128.383,131.696,136.645,140.563,144.482,149.431,152.842,159.746,163.664,168.147,173.097,177.015,181.964,185.883,190.832,193.253,196.607,199.494,202.381,205.735,212.639,217.122,220.574,223.933,227.385,231.303,236.253,241.202,244.654,247.541,251.46,256.409,259.819,262.706,267.655,272.139,275.026,278.413,283.363,285.783,290.732,291.849,299.219,303.703,306.124,313.494,318.90900000000005,322.292,327.242" y="247.98000000000002" svg_rhmargin="330.129" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">might have been weakened. It was reported that 1.5 mg/mL of</text>
  <text x="85.039,89.988,93.906,98.39,102.873,106.791,109.212,113.13,118.08,125.45,129.933,134.882,140.652,144.57,149.52,154.469,156.89,161.839,167.637,172.587,177.536,184.44,189.389,192.841,196.76,201.243,206.192,208.613,213.096,215.984,219.90200000000002,225.689,228.576,233.525,237.443,243.206,247.124,252.074,257.023,260.475,264.393,267.845,271.298,273.718,278.668,283.617,289.409,294.359,297.246,303.016,306.468,311.417,314.869,317.756,322.24,326.158" y="258.922" svg_rhmargin="330.076" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">bevacizumab could downregulate the expression of surface</text>
  <text svg_rhmargin="193.263" x="85.039,87.46,92.409,95.296,99.214,103.698,107.15,109.571,114.52,117.972,124.156,128.639,133.589,138.538,144.735,148.654,153.603,156.024,158.445,162.928,167.411,171.33,176.279,179.731,185.893,188.314,193.263" y="269.86300000000006" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">integrins and collagens in </text>
  <text x="199.445" y="269.86300000000006" svg_rhmargin="204.394" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="204.378,209.327,212.779,217.728,222.678,225.099,229.582,233.034,235.921,242.134,246.052,249.97,252.391,254.812,258.264,260.685,266.908,271.391,276.34,281.289,287.43,290.317,295.266,300.216,303.668,309.823,314.772,318.691,321.112,325.595" y="269.86300000000006" svg_rhmargin="330.078" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">broblast cells, and thus delay</text>
  <text x="85.039,88.957,93.906,96.327,99.214,104.164,108.082,110.503,112.924,117.407,119.828,122.625,126.543,128.964,133.913,137.365,142.315,145.767,149.685" y="280.861" svg_rhmargin="152.106" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">epithelial closure.</text>
  <text svg_rhmargin="163.92" x="152.164,154.33,158.042,161.755,163.92" y="280.86300000000006" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[29] </text>
  <text x="166.677,171.626,176.576,180.028,182.915,187.864,191.783,195.235,202.605,207.554,211.007,214.925,217.346,220.137,223.024,227.973,231.89100000000002,234.65,238.568,243.517,248.467,252.385,256.303,261.253,264.14,267.592,272.075,274.962,277.383,282.333,287.282,290.734,293.551,298.501,301.388,304.153,308.071,313.021,315.441,318.329,323.278,327.196" y="280.86300000000006" svg_rhmargin="330.083" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Furthermore, the concentrations of epithe-</text>
  <text svg_rhmargin="181.532" x="85.039,87.46,89.881,94.364,96.78500000000001,101.082,105.565,109.017,113.967,120.871,123.758,128.707,133.0,135.887,140.37,144.288,147.175,152.125,155.577,157.998,162.309,167.258,171.741,175.193,177.614,181.532" y="291.805" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">lial growth factor, basic </text>
  <text x="185.839" y="291.805" svg_rhmargin="190.788" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="190.828,195.777,199.229,204.179,209.128,211.549,216.032,219.484,222.371,226.656,231.139,234.591,239.541,246.445,249.332,254.281,258.574,261.461,265.944,269.862,272.749,277.699,281.151,283.572,287.883,290.304,295.253,298.705,303.654,306.075,308.496,313.446,316.333,318.754,321.175,326.124" y="291.805" svg_rhmargin="330.042" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">broblast growth factor, insulin-like</text>
  <text x="85.038,89.521,92.973,97.923,104.827,107.714,112.663,115.254,118.142,122.625,126.543,129.43,134.38,137.832,140.719,145.668,148.089,150.687,155.17,160.119,165.068,167.637,170.525,175.474,182.844,187.794,191.246,193.829,198.778,202.697,206.615,210.067,215.016,218.468,220.889,224.341,226.936,229.823,234.306,238.225,241.112,246.061,249.513,252.107,254.528,259.477,263.396,266.848,270.766,275.249,278.701,282.619,287.56800000000004,290.203,292.624,297.57300000000004,300.124,305.074,309.557,312.444,314.865,318.783,323.733,326.62" y="302.746" svg_rhmargin="330.072" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">growth factor-1, and tumor necrosis factor increased in patients</text>
  <text x="85.038,87.925,91.377,95.295,99.779,102.666,106.584,111.533,117.295,124.199,126.62,129.507,134.45600000000002,140.199,145.148,149.066,153.55,158.033,161.951,164.372,168.29,173.24,180.61,185.093,190.042,195.812,200.295,205.245,210.19400000000002,215.881,218.769,223.718,228.667,232.119,237.878,245.248,247.669,252.152,257.101,259.988,265.714,268.134,273.084,277.002,280.454,284.372,288.856,292.308,296.226,301.996,305.914,310.863,314.315,319.265,323.183,327.666" y="313.688" svg_rhmargin="330.087" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">treated with bevacizumab and thus might increase corneal</text>
  <text x="85.038,88.49,93.439,96.891,100.81,104.728,109.677,112.565,114.985,119.935,122.356,124.777,127.198,130.085,134.568,137.59,140.478,145.42700000000002,148.419,152.337,157.287,164.657,169.606,172.027,174.448,178.366,182.85,185.737,188.158,193.107,198.056,201.508" y="324.686" svg_rhmargin="203.929" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">susceptibility to complications.</text>
  <text x="203.981,206.147,209.86,213.572" y="320.661" svg_rhmargin="215.737" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[38]</text>
  <text x="93.997,99.496,101.99,109.361,111.911,114.799,119.395,122.282,124.837,129.787,134.871,138.386,140.807,144.566,148.081,153.03,157.094,162.043,165.825,170.308,173.76,177.56,182.605,187.555,192.583,195.077,197.572,201.49,206.076,209.08,211.501,216.563,221.512,225.294,230.243,232.777,237.26,240.827,243.248,247.063,250.578,255.527,260.556,265.601,268.022,272.971,276.769,281.815,285.733,289.525,292.412,297.008,301.958,305.966,310.915,314.696,317.19,322.236,325.123" y="335.628" svg_rhmargin="330.072" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Limitations, such as publication bias, should be taken into</text>
  <text x="85.039,89.523,93.543,97.568,102.517,107.546,112.591,115.478,117.807,124.78,129.825,133.743,138.692,141.107,143.601,148.55,151.538,155.456,159.021,164.067,167.581,171.5,174.498,176.992,181.942,186.425,188.841,191.729,196.835,200.75300000000001,203.071,206.586,210.611,214.125,219.075,221.609,224.496,227.948,230.396,235.345,238.232,240.657,243.544,248.594,251.088,254.54,256.928,264.298,268.323,271.21,275.806,278.811,283.294,288.335,292.818,295.365,299.848,303.415,305.909,309.424,311.84499999999997,314.186,319.231,323.149" y="346.57" svg_rhmargin="330.053" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">account when interpreting the results of this meta-analysis. Few</text>
  <text x="85.039,88.554,91.441,96.491,101.537,104.031,107.949,111.401,113.782,121.265,125.183,130.222,133.11,135.665,140.614,145.699,149.617,154.566,156.981,161.93,165.938,170.983,173.478,177.961,181.413,183.795,187.31,191.793,199.272,204.317,207.204,212.254,219.625,223.077,225.52,230.003,235.044,239.99300000000002,242.358,245.245,250.351,254.269,256.587,261.07,266.168,269.682,273.601,278.64,282.558,286.476,288.901,293.85,296.737,299.162,302.677,306.595,309.14,313.058,317.643,322.236,327.185" y="357.568" svg_rhmargin="330.072" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">studies mentioned ocular symptoms and the absence of relevant</text>
  <text x="85.039,89.989,95.074,98.992,102.557,105.444,107.999,112.949,118.034,122.983,127.558,130.052,133.567,137.485,140.937,147.003,151.595,154.016,157.548,162.497,168.546,171.041,173.535,180.905,183.456,186.343,189.795,195.872,198.759,203.865,207.78300000000002,213.787,218.27,223.367,225.861,228.282,230.794,233.681,238.16400000000002,244.286,247.173,252.122,258.176,263.221,266.736,271.219,278.123,284.197,288.68,294.685,299.73" y="368.51" svg_rhmargin="303.648" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">questionnaires also limits the ability to draw a de</text>
  <text x="303.705" y="368.51" svg_rhmargin="308.654" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="308.694,313.739,316.234,319.121,321.676,326.159" y="368.51" svg_rhmargin="330.077" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">nitive</text>
  <text x="85.039,88.958,94.053,99.003,103.011,105.547,110.497,114.064,116.601,121.666,126.615,129.036,133.742,142.708,147.773,151.288,154.175,158.828,163.873,166.76,171.413,174.3,179.365,183.283,186.851,190.769,195.412,198.927,201.814,206.879,211.828,214.365,218.283,221.73499999999999,226.497,231.447,233.983,238.93200000000002,243.621,248.57,253.599,256.486,261.196,266.145,269.713,274.662,279.261,281.682,286.747,290.665,295.308,299.342,304.292,311.777,316.843,319.263,323.297,326.185" y="379.451" svg_rhmargin="330.103" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">conclusion. Most of these studies did not provide complete</text>
  <text x="85.039,87.552,92.501,95.48,100.521,104.064,111.434,116.009,118.896,121.409,126.358,131.30700000000002,135.638,138.525,143.566,147.018,151.333,154.22,159.27,163.18800000000002,167.49,171.973,177.014,181.497,185.574,189.118,192.661,196.579,200.825,204.743,209.329,213.338,218.288,221.266,224.81,227.231,231.5,235.014,240.055,243.973,248.92200000000003,253.264,257.747,261.199,265.51,268.397,273.438,277.356,281.658,286.607,290.162,294.171,299.121,304.162,308.171,311.715,316.198,319.177,321.689,326.172" y="390.449" svg_rhmargin="330.09" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">information for the adverse events, such as the preoperative</text>
  <text x="85.039,89.989,94.053,99.003,101.537,106.02,109.472,114.519,118.437,123.476,128.522,133.471,136.005,138.892,141.447,146.397,151.346,156.414,160.897,165.938,170.887,175.859,178.864,183.813,187.731,192.753,195.641,198.196,205.566,208.117,213.067,217.55,222.574,227.619,230.506,235.499,238.387,243.436,247.354,252.337,256.362,261.312,268.778,273.823,276.244,278.755,282.78,287.264,290.264,292.758,297.708,302.736,305.157,310.163,316.682,319.176,322.691,327.641" y="401.391" svg_rhmargin="330.062" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ocular condition and the timing of the complication. Also,</text>
  <text x="85.039,89.989,92.523,97.006,101.083,104.598,108.112,112.03,114.122,119.071,121.605,125.12,129.038,133.623,137.138,141.163,144.615,146.662,153.635,157.66,161.175,165.09300000000002,167.184,169.679,174.628,178.636,181.13,186.176,191.125,195.133,200.08200000000002,202.163,204.657,209.60600000000002,211.744,214.631,219.681,223.59900000000002,225.69,230.736,235.685,237.765,244.203,250.748,256.7,260.215,262.63599999999997,264.75,270.703,275.652,279.66,283.175,287.093,289.184,296.157,300.182,303.697,307.615,309.706,314.189,316.283,319.17,323.2" y="412.332" svg_rhmargin="330.104" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">diverse diseases were included in the 18 RCTs. There were a few</text>
  <text x="85.039,88.554,95.925,100.516,103.011,105.505,108.392,111.968,114.462,118.381,122.456,127.405,131.244,134.759,137.646,142.752,147.701,150.235,154.154,157.606,161.517,164.404,169.51,173.993,176.88,180.792,184.306,188.331,193.281,198.309,201.824,204.711,208.797,213.746,217.584,221.099,225.124,229.607,233.627,237.142,241.06,244.909,249.954,253.872,258.911,261.406,265.889,269.341,273.311,277.794,282.835,287.318,291.339,294.854,298.368,302.286,306.192,310.111,314.696,318.721,323.67,326.658" y="423.274" svg_rhmargin="330.11" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">small-sized studies that reported severe ocular adverse events</text>
  <text x="85.039,89.523,92.523,95.41,99.496,102.948,110.891,115.374,120.473,123.36,125.915,128.802,135.383,140.798,147.798,152.747,160.724,163.611,167.187,171.212,175.695,178.695,186.065,190.09,195.136,198.023,205.964,208.969,213.918,217.37,225.41,231.847,239.356,245.79399999999998,253.756,258.239,261.239,264.126,268.212,271.664,279.607,284.653,288.571,292.136,296.619,299.619,304.569,309.653,312.148,316.631,320.198,323.085,327.681" y="434.272" svg_rhmargin="330.102" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">after anti-VEGF treatment for CNV after keratoplasty.</text>
  <text x="85.039,91.559,96.508,99.496,104.541,108.056,110.943,115.993,120.942,125.517,128.522,132.44,134.984,139.468,141.88899999999998,146.153,153.523,158.625,162.14,165.027,169.227,174.176,177.063,181.359,184.246,189.296,193.321,200.691,204.887,211.86,215.778,219.343,223.261,227.507,231.425,236.01,239.525,243.443,247.689,251.204,255.122,258.687,261.182,265.1,268.552,272.804,277.396,282.346,287.295,291.569,295.488,300.527,305.572,307.993,312.942,317.194,322.239,327.189" y="445.214" svg_rhmargin="330.076" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Unfortunately, most of them were case series and could not</text>
  <text x="85.039,89.989,93.90700000000001,96.435,98.929,103.879,107.943,110.364,115.426,120.376,124.384,129.333,131.81,134.305,139.25400000000002,141.732,144.619,149.725,152.146,155.59799999999998,158.116,165.486,169.511,172.516,176.999,179.999,184.482,189.523,194.006,196.552,201.036,204.602,207.097,210.612,213.033,215.544,218.431,223.38000000000002,225.919,230.402,235.443,240.488,242.909,245.931,248.352,253.414,258.363,260.784,263.335,266.222,271.272,275.19,277.679,285.049,289.074,291.961,296.557,299.562,304.045,309.086,313.569,316.115,320.599,324.165,326.66" y="456.155" svg_rhmargin="330.112" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">be included in this meta-analysis. In addition, the meta-analysis</text>
  <text x="85.039,92.013,96.496,99.948,104.882,107.376,109.871,117.241,119.792,122.679,126.709,131.65800000000002,136.517,141.466,145.949,150.86,153.747,158.854,162.77200000000002,167.641,171.559,176.144,179.031,183.061,187.653,192.603,196.157,198.651,202.57,207.155,210.042,212.598,217.643,222.592,227.451,232.401,235.288,240.207,243.094,248.144,252.062,256.932,261.415,266.512,270.995,275.016,278.53,282.045,285.963,290.833,294.751,299.393,303.312,308.351,311.238,314.814,317.235,322.127,326.611" y="467.153" svg_rhmargin="330.063" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">was limited by the categorization of the adverse events, as</text>
  <text x="85.039,89.989,94.053,97.568,101.486,105.051,107.546,112.495,116.503,121.452,124.667,127.161,132.11,135.325,138.212,143.262,147.18,150.406,159.372,163.388,166.275,171.381,176.331,181.359,184.874" y="478.095" svg_rhmargin="187.295" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">described in the Methods.</text>
  <text x="93.997,101.367,105.285,109.769,113.687,117.139,120.026,124.975,128.894,131.315,135.233,138.685,142.137,144.558,147.967,150.854,155.803,158.224,161.676,165.031,172.401,176.319,179.206,183.689,186.577,191.06,196.009,200.492,202.913,207.396,210.848,213.269,216.721,220.134,223.586,228.535,233.485,240.389,244.307,249.256,252.618,255.505,260.454,264.938,267.825,271.212,274.099,279.049,282.967,286.293,290.776,295.725,303.095,305.516,310.466,312.887,316.339,319.226,322.678,327.161" y="489.037" svg_rhmargin="330.048" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Nevertheless, this meta-analysis showed that the administra-</text>
  <text x="85.039,87.927,90.348,95.297,100.246,103.691,108.641,111.528,114.973,119.456,124.405,127.842,132.325,137.274,140.162,142.582,145.47,151.907,157.323,164.227,169.17600000000002,172.628,177.111,181.594,185.512,190.462,193.349,196.778,199.199,204.14800000000002,207.607,210.494,215.444,219.362,222.8,227.75,231.668,236.617,239.038,243.522,246.974,250.409,254.893,259.842,262.729,266.647,270.099,272.52,277.47,280.922,284.368,287.82,291.738,296.221,303.591,307.51,312.459,315.346,318.836,321.723,326.672" y="500.035" svg_rhmargin="330.124" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">tion of an anti-VEGF agent in the ocular anterior segment for</text>
  <text x="85.039,87.927,91.379,95.297,99.78,102.667,110.038,113.956,118.905,121.792,126.481,131.43,134.317,138.953,143.902,146.789,150.708,154.16,158.643,163.126,165.547,170.496,177.866,182.549,187.032,191.981,196.93,201.598,206.547,210.465,215.415,219.898,224.381,227.833,231.752,236.701,239.122,243.605,247.057,251.712,256.195,258.616,263.099,268.049,271.967,276.917,284.287,288.77,293.437,300.341,304.824,308.276,312.939,316.391,320.874,323.761,327.679" y="510.976" svg_rhmargin="330.1" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">treatment of pterygium and neovascular glaucoma was safe.</text>
  <text x="85.039,92.508,97.458,104.362,108.28,112.763,116.682,120.134,122.555,124.836,129.786,134.735,138.65300000000002,140.88,143.767,148.716,150.971,153.859,158.808,162.726,164.974,167.395,169.816,177.186,179.607,182.494,186.412,191.36100000000002,193.603,197.522,202.005,204.426,209.375,213.293,218.243,222.161,226.079,228.5,230.793,233.68,238.63,242.082,244.969,249.918,253.836,257.288,259.535,262.987,266.906,270.358,274.276,278.759,282.211,286.129,291.07800000000003,293.323,296.775,301.724,306.674,311.623,314.044,318.993,321.215,326.165" y="521.918" svg_rhmargin="330.083" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">However, due to the limited evidence, further research should be</text>
  <text x="85.039,89.989,93.907,97.359,100.246,105.196,108.648,116.018,119.936,124.885,132.603,137.552,142.501,150.121,153.009,157.958,161.876,169.567,173.019,177.502,180.389,184.307,187.194,191.677,199.387,204.336,207.223,214.863,219.813,222.234,225.121,228.008,231.926,235.378,239.297,244.246,247.133,254.831,259.78,264.73,268.182,272.665,277.148,281.06600000000003,288.732,293.216,298.165,301.052,303.473,306.36,312.798,318.214,325.118" y="532.9159999999999" svg_rhmargin="330.067" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">performed on the safety of different dosage anti-VEGF</text>
  <text x="85.039,89.523,94.472,101.842,104.263,109.213,111.634,115.086,117.973,121.425,125.908,128.795,131.216,136.165,141.114,145.925,148.346,153.29500000000002,158.057,163.007,167.49,170.377,172.798,176.716,181.666,184.553,188.005,192.753,199.657,202.077,204.965,209.91400000000002,214.692,221.13,228.5,234.938,239.75,244.7,248.152,252.903,257.852,261.771,265.223,269.706,272.593,277.542,282.492,284.913,289.396,292.848,295.735,300.218,302.639,307.44,314.344,316.765,321.248,325.166" y="543.858" svg_rhmargin="330.115" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">administration in patients with CNV or keratoplasty. Given</text>
  <text x="85.039,87.927,92.876,96.79400000000001,98.873,103.822,108.771,111.659,115.577,120.526,123.413,125.834,130.317,132.738,134.871,138.324,140.744,144.196,149.146,152.59799999999998,154.657,157.544,162.493,165.945,168.036,171.954,176.904,180.356,185.305,189.223,193.707,196.128,198.252,202.171,207.12,209.541,212.428,217.378,221.296,223.717,226.138,230.621,233.042,235.159,240.108,244.026,248.51,250.93,253.351,258.301,262.784,264.865,267.286,272.235,274.332,279.282,283.765,286.652,289.073,292.991,297.941,300.828,304.28,306.363,313.267,315.688,318.575,323.524,325.638" y="554.799" svg_rhmargin="330.121" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">the potential risks for corneal epithelial healing in patients with a</text>
  <text x="85.039,89.989,92.41,95.862,98.749,103.698,107.15,111.63300000000001,113.555,118.504,121.391,123.306,128.255,132.174,135.626,140.109,142.996,147.945,152.895,155.316,159.799,163.251,166.138,170.621,173.042,175.008,177.429,180.316,182.208,184.629,188.081,190.031,194.514,198.433,201.885,206.368,208.286,210.707,218.077,223.026,227.976,231.428,234.315,238.798,243.747,246.63400000000001,248.536,251.424,256.373,258.287,263.237,267.72,272.20300000000003,274.161,281.531,286.481,289.933,293.851,295.76,300.243,303.13,306.018,309.936,314.885,317.772,320.193,325.143" y="565.741" svg_rhmargin="330.092" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">history of keratoplasty, it is very important to pay more attention</text>
  <text x="85.039,87.927,92.876,95.074,97.961,102.91,106.828,109.076,111.497,116.447,119.334,123.252,127.735,131.187,133.608,136.495,140.978,143.205,148.154,151.041,153.239,156.126,161.075,164.993,167.242,171.16,176.109,179.561,184.511,188.429,192.912,195.333,197.515,201.433,206.382,208.803,211.69,216.64,220.558,222.979,225.4,230.349,237.719,239.976,244.926,248.844,251.731,256.68,260.133,264.051,266.281,270.764,275.713,283.084,285.504,290.454,292.875,296.327,299.214,303.132,306.584,309.005,313.955,318.438,320.704,325.188" y="576.739" svg_rhmargin="330.137" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">to the integrity of the corneal epithelium before administering an</text>
  <text x="85.039,89.523,94.472,97.359,99.78,102.667,109.105,114.521,121.425,126.374,129.372,133.855,138.338,142.256,147.206,150.093,153.125,155.546,160.495,163.383,168.33200000000002,171.323,174.21,179.16,183.078,186.063,191.012,194.93,199.88,202.301,206.784,210.236,213.275,217.758,222.707,225.594,229.513,232.965,235.386,240.335,243.787,246.779,250.231,254.149,258.632,266.003,269.921,274.87,277.758" y="587.6800000000001" svg_rhmargin="280.179" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-VEGF agent into the ocular anterior segment.</text>
  <text x="85.039,91.636,97.154,102.672,108.587,114.304,122.084,124.838,130.555,136.47,142.187,150.856,156.573,162.488,166.132" y="614.331" svg_rhmargin="171.356" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">Acknowledgments</text>
  <text x="85.039,90.921,95.871,100.354,105.303,110.253,113.705,115.822,118.71,123.65899999999999,125.8,128.687,133.637,137.555,139.69,142.577,147.526,149.947,152.368,157.318,164.222,166.643,171.592,176.07500000000002,178.24,183.189,187.107,192.057,197.006,199.427,203.345,205.451,212.355,217.305,222.25400000000002,224.386,229.336,233.819,238.302,242.22,244.342,249.291,253.21,255.63,260.58,264.498,269.447,271.61,274.031,278.98,281.134,285.617,290.101,293.553,295.973,300.923,305.872,309.324,311.464,314.916,317.803,321.721,326.671" y="630.261" svg_rhmargin="330.123" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Thanks to the following people who have helped in various steps</text>
  <text x="85.039,89.989,92.876,95.868,98.755,103.705,107.623,110.608,115.557,119.009,123.959,126.379,130.298,134.216,137.103,139.524,142.581,149.019,153.969,158.918,163.401,166.392,170.875,175.824,180.773,183.194,186.177,192.058,196.542,201.491,204.488,210.925,215.875,220.824,225.774,228.195,231.189,235.672,240.622,245.57100000000003,248.537,254.975,259.924,262.812,267.295,272.244,274.665,277.677,284.115,289.064,294.013,298.963" y="641.259" svg_rhmargin="301.384" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">of the project: Cong Sun, Tao Zhou, and Yu-gui Zhou.</text>
  <text x="85.039,91.636,97.552,101.195,107.111,112.827,116.764,119.905,125.423,131.14,137.055,140.699,144.636,147.39,153.306,159.221,162.865,165.619,171.336,177.251" y="669.89" svg_rhmargin="182.475" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">Author contributions</text>
  <text svg_rhmargin="141.239" x="85.039,91.943,96.427,99.314,103.797,106.809,110.727,115.676,119.128,123.612,126.499,128.92,133.869,138.818,141.239" y="685.821" style="fill:#171615;font-family:DPOGHN+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Data curation: </text>
  <text x="144.227,148.71,153.659,156.08,158.967,163.917,168.866,173.34900000000002,176.371,183.84,188.789,193.273,198.222,202.705,205.126,208.118,213.534,215.955,218.842,222.294,227.243,231.726,236.675,239.695,245.577,247.997,252.481,257.43,259.851,262.825,270.195,275.144,278.132,285.036,287.457,291.94,296.89" y="685.821" svg_rhmargin="299.311" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Shitong Huang, Bi-shan Tian, Ou Xiao.</text>
  <text svg_rhmargin="114.619" x="85.039,94.006,97.458,99.879,102.766,105.187,110.136,114.619" y="696.762" style="fill:#171615;font-family:DPOGHN+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="122.121" x="117.638,122.12100000000001" y="696.762" style="fill:#171615;font-family:DPOGHO+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="178.742" x="125.121,130.071,133.523,135.944,140.427,142.848,147.797,152.28,154.701,157.662,162.611,166.063,170.547,173.434,176.321,178.742" y="696.762" style="fill:#171615;font-family:DPOGHN+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">original draft: </text>
  <text x="181.758,186.241,191.191,193.611,196.499,201.448,206.397,210.88,213.902,221.371,226.321,230.804,235.753,240.236,242.65699999999998,245.649,251.065,253.486,256.373,259.825,264.774,269.257,274.206,277.226,283.108,285.529,290.012,294.961,297.382,300.356,306.794,311.743,316.693,321.176" y="696.762" svg_rhmargin="324.063" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Shitong Huang, Bi-shan Tian, Yong-</text>
  <text x="96.945,100.397,105.346,109.829,114.77799999999999,117.75,124.188,128.671,133.621,138.104" y="707.76" svg_rhmargin="140.525" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Juan Yang.</text>
  <text svg_rhmargin="114.619" x="85.039,94.006,97.458,99.879,102.766,105.187,110.136,114.619" y="718.702" style="fill:#171615;font-family:DPOGHN+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="122.121" x="117.638,122.12100000000001" y="718.702" style="fill:#171615;font-family:DPOGHO+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="193.029" x="125.121,128.573,132.492,136.975,139.396,143.314,150.218,153.183,161.584,164.579,168.497,173.446,175.867,178.754,181.175,186.125,190.608,193.029" y="718.702" style="fill:#171615;font-family:DPOGHN+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">review &amp; editing: </text>
  <text svg_rhmargin="315.787" x="196.045,200.528,205.477,207.898,210.785,215.735,220.684,225.167,228.189,235.658,240.607,245.091,250.04,254.523,256.944,259.936,264.419,269.369,271.79,274.677,279.16,284.109,289.058,292.08,298.518,303.467,308.417,313.366,315.787" y="40.71199999999999" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Shitong Huang, Shi-you Zhou. </text>
  <text x="345.09,351.885,357.602,361.047,366.764,370.701,376.418,382.333,387.851,393.567" y="40.71199999999999" svg_rhmargin="398.791" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">References</text>
  <text x="349.342,351.748,355.872,358.278,361.586,366.951,372.704,376.829,380.953,384.68899999999996,388.967,393.869,400.079,402.096,406.315,413.787,417.911,422.035,425.771,431.995,435.26,439.385,443.616,451.089,453.106,457.393,462.758,466.883,469.288,471.306,473.712,477.448,481.184,484.06,487.325,491.45,493.467,497.302,500.17900000000003,504.388,507.653,511.778,515.902,520.091,522.497,526.621,529.886,531.904,533.921,537.657,539.6740000000001,543.957,547.692,550.569,554.694,560.447,562.853,566.978,571.281,573.687,577.423,580.688,583.094,587.218" y="55.16899999999998" svg_rhmargin="590.095" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[1] Kwong TQ, Mohamed M. Anti-vascular endothelial growth factor</text>
  <text x="361.587,363.993,368.117,371.383,374.259,377.995,382.12,384.137,387.493,390.37,392.029,394.046,398.171,399.909,404.034,408.158,412.283,414.688,418.813,422.549,424.566,430.708,434.832,436.85,441.065,444.801,448.536,450.553,452.232,455.497,459.622,462.498,465.375,468.64,472.764,475.17,476.948,481.073,483.95,487.215,489.23199999999997,490.951,494.216,498.34,502.465,504.871,507.747,511.872,515.608,518.873,521.749,524.626,526.643,529.909,532.786,534.543,538.279,542.404,546.529,548.262,550.668,554.793,558.058,559.771,562.177,566.301,568.707,572.831,575.708,578.973,580.99,582.729,587.242" y="64.12599999999998" svg_rhmargin="590.119" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">therapies in ophthalmology: current use, controversies and the future. Br</text>
  <text x="361.587,364.464,366.973,372.338,374.356,376.373,380.498,383.017,387.141,391.266,395.002,397.878,404.02,407.756,411.021,415.216,417.233,419.695,423.82,427.944,432.069,436.193,438.21,442.335,446.459,448.549,452.673,456.798" y="73.13999999999999" svg_rhmargin="460.922" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">J Clin Pharmacol 2014;78:699</text>
  <text x="460.913" y="73.13999999999999" svg_rhmargin="464.649" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="464.655,468.779,472.904,477.028" y="73.13999999999999" svg_rhmargin="479.045" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">706.</text>
  <text x="349.342,351.748,355.872,358.278,361.586,366.099,369.835,373.96,377.696,380.57300000000004,382.334,384.74,386.757,388.456,393.822,397.087,401.212,405.336,409.072,410.849,414.585,420.727,422.74399999999997,424.455,428.191,431.456,433.473,435.491,439.227,440.951,446.316,448.33299999999997,450.078,453.343,455.749,457.447,461.183,463.201,465.218,466.971,472.336,476.46,478.866,482.131,485.008,487.025,491.15,494.027,495.769,498.645,501.91,505.646,511.868,515.133,519.258,521.664,523.376,527.501,530.377,533.643,536.52,538.229,542.353,544.7589999999999,546.505,550.63,553.895,557.631,561.367,564.632,566.649,569.914,574.039,580.181,583.917,588.041" y="82.09699999999998" svg_rhmargin="590.058" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[2] Bahar I, Yeung SN, Sella R, et al. Anterior segment uses of bevacizumab.</text>
  <text x="361.587,366.953,371.078,373.955,376.832,379.389,385.532,389.657,391.675,395.8,398.269,404.412,408.537,412.726,415.133,419.258,422.995,425.013,431.156,435.281,437.298,439.828,443.953,448.079,452.204,456.329,458.347,462.472,466.597,468.616,472.741,476.866" y="91.05399999999997" svg_rhmargin="480.99" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Curr Opin Ophthalmol 2012;23:303</text>
  <text x="481.038" y="91.05399999999997" svg_rhmargin="484.774" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="484.78,488.905,493.03" y="91.05399999999997" svg_rhmargin="495.047" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">16.</text>
  <text x="349.342,351.748,355.872,358.278,361.586,369.058,373.183,375.2,378.936,380.634,385.146,387.163,388.796,393.309,397.434,400.699,403.964,408.089,410.495,413.76,416.166,420.29,423.262,425.668,428.933,430.576,435.089,437.106,438.739,444.103,449.857,453.593,457.329,459.034,464.398,470.622,472.639,474.283,477.548,479.954,481.652,485.388,487.405,489.42199999999997,491.063,494.799,498.535,501.411,503.817,507.082,513.224,515.325,518.59,520.201,523.077,526.813,529.219,532.559,534.965,538.701,540.326,544.451,546.857,548.546,552.67,555.936,559.671,563.407,566.673,568.69,571.955,576.08,582.221,585.957" y="100.01199999999994" svg_rhmargin="590.081" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[3] Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab</text>
  <text x="361.587,365.323,368.588,371.465,374.342,378.466,381.343,384.206,387.082,390.818,394.943,396.96,401.156,403.173,406.438,410.563,416.704,420.44,424.565,427.402,429.808,433.933,436.81,439.704,443.828,447.094,451.218,454.954,458.69,461.566,464.832,468.956,470.973,474.709,477.586,480.463,484.199,487.934,491.2,493.606,496.482,499.747,501.765,505.501,507.907,511.172,515.297,518.16,524.302,528.038,531.303,535.507,537.524,541.26,544.137,546.958,551.083,554.348,558.084,561.349,565.473,568.738,571.615,575.351,577.757,579.774,583.899,588.114" y="108.96900000000005" svg_rhmargin="590.131" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">versus ranibizumab for neovascular age-related macular degeneration.</text>
  <text x="361.587,366.952,371.076,374.342,378.466,381.343,385.078,389.203,392.46799999999996,395.033,400.787,404.523,406.929,410.665,414.789,418.525,421.402,424.667,427.176,430.912,434.648,437.525,439.931,442.482,447.847,451.112,454.848,457.334,461.46,465.584,469.708,473.833,475.85,481.215,486.968,491.093,495.217,499.342,503.466,507.674,511.798" y="117.92600000000004" svg_rhmargin="513.815" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Cochrane Database Syst Rev 2014;CD011230.</text>
  <text x="349.342,351.748,355.872,358.278,361.586,369.058,372.794,376.919,380.655,386.926,394.398,396.415,402.686,408.051,412.175,415.911,420.035,423.771,430.01,435.763,437.78,444.013,447.749,451.485,454.361,456.767,460.113,466.254,468.272,471.537,477.8,481.536,485.661,489.397,492.662,495.539,498.415,501.68,507.902,511.167,514.903,518.168,522.358,524.764,527.641,533.866,537.602,540.008,542.414,545.679,548.5559999999999,554.841,556.858,560.983,563.389,566.265,570.001,573.737,575.754,578.16,581.037,584.302,588.038" y="126.88300000000004" svg_rhmargin="590.055" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[4] Wang W, Zhang X. Systemic adverse events after intravitreal</text>
  <text x="361.587,365.712,368.977,372.713,376.449,379.714,381.731,384.996,389.194,395.336,399.072,403.197,405.407,409.143,412.408,415.285,418.161,422.357,425.23400000000004,427.459,430.336,434.072,438.196,440.214,444.338,446.355,449.621,453.745,459.887,463.623,467.748,470.032,472.438,476.562,479.439,481.654,485.39,489.125,492.391,494.797,497.673,500.938,502.956,506.692,509.098,512.363,516.488,518.784,524.926,528.662,531.927,536.051,538.069,541.805,544.6819999999999,546.958,551.082,554.348,558.084,561.349,565.473,568.738,571.615,575.351,577.757,579.774,583.899,588.114" y="135.89700000000005" svg_rhmargin="590.131" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab versus ranibizumab for age-related macular degeneration:</text>
  <text x="361.587,365.323,367.823,373.966,377.231,379.637,383.373,385.779,389.514,393.639,397.375,399.392,403.128,406.005,408.129,411.006,413.02299999999997,415.498,419.623,424.136,428.26,431.996,434.49,440.631,444.756,448.02099999999996,450.532,454.657,458.781,462.905,467.03,469.126,473.25,475.268,478.533,482.657,486.782,490.906,495.03,499.155,503.279" y="144.85400000000004" svg_rhmargin="505.296" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">a meta-analysis. PLoS One 2014;9:e109744.</text>
  <text x="349.342,351.748,355.872,358.278,361.586,366.951,370.687,373.952,377.217,380.953,385.078,387.095,391.22,394.579,396.596,400.332,404.457,405.861,411.225,413.243,415.26,416.745,421.258,424.994,429.119,431.136,433.542,437.278,439.684,442.949,449.091,451.108,452.572,460.044,462.062,464.079,465.554,471.778,475.903,478.779,481.656,484.921,486.938,491.063,493.08,494.578,500.802,502.819,504.272,509.174,513.298,516.563,517.991,521.256,523.662,526.068,529.334,532.599,535.005,536.472,540.597,543.0029999999999,544.466,548.59,550.607,553.013,555.419,558.684,561.561,564.826,568.951,571.357,572.81,576.934,581.059,583.935,587.266" y="153.812" svg_rhmargin="590.143" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[5] Razeghinejad R., Banifatemi M., Hosseini H. The effect of different doses</text>
  <text x="361.587,365.712,368.118,372.755,375.632,379.756,383.881,387.211,391.335,395.46,397.477,401.602,405.726,408.991,411.397,413.414,417.15,420.886,422.903,427.573,431.697,434.962,438.698,442.434,445.699,447.717,450.982,455.18,461.321,465.057,469.182,473.831,477.955,482.08,486.699,489.105,493.23,496.495,501.156,504.032,507.298,510.563,514.687,517.564,520.44,523.706,527.83,531.095,534.36,539.024,541.9,545.636,548.042,551.307,555.974,560.099,562.505,567.142,570.408,574.532,577.797,579.815,582.691,585.956" y="162.769" svg_rhmargin="590.08" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">of subconjunctival bevacizumab on the recurrence rate of excised</text>
  <text x="361.587,365.712,368.588,370.606,376.747,380.483,383.36,387.096,389.648,393.773,396.179,399.444,402.32,406.056,409.792,411.81,415.934,422.076,424.093,426.666,431.179,435.303,437.321,439.338,441.858,445.594,449.719,452.984,455.464,459.977,463.242,465.259,468.995,472.26,474.795,480.936,485.061,489.185,491.591,495.327,497.344,503.486,507.611,509.628,512.152,516.277,520.401,524.525,528.65,530.667,534.792,538.916,543.041,545.145,549.269" y="171.726" svg_rhmargin="553.393" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">primary pterygium. Bull Soc Belge Ophtalmol 2013;322:13</text>
  <text x="553.379" y="171.726" svg_rhmargin="557.115" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="557.12,561.246,565.371" y="171.726" svg_rhmargin="567.388" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">20.</text>
  <text x="349.342,351.748,355.873,358.279,361.587,366.952,370.688,373.953,377.218,380.954,385.078,387.096,391.22,394.58,396.597,400.333,404.458,408.582,416.053,421.418,423.435,427.573,432.086,435.822,439.946,442.028,444.434,448.17,450.576,453.841,459.983,462.0,466.178,473.651,475.668,479.784,483.52,487.645,491.769,495.034,499.228,503.352,505.37,509.494,513.619,516.884,519.29,521.307,525.043,528.779,530.796,534.942,539.066,542.331,546.067,549.803,553.139,555.156,558.421,562.546,568.688,572.423,576.548,580.69,583.095,587.22" y="180.683" svg_rhmargin="590.097" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[6] Razeghinejad MR, Banifatemi M. Subconjunctival bevacizumab for</text>
  <text x="361.588,365.712,368.589,370.606,376.748,380.484,383.361,387.097,389.932,394.057,396.463,399.728,402.604,406.34,410.076,412.094,416.218,422.36,425.192,428.457,432.582,435.847,437.864,440.741,442.759,446.883,451.099,453.116,455.917,459.65299999999996,462.437,465.314,469.05,473.174,477.298,481.423,487.565,489.582,492.847,496.112,500.237,503.082,506.347,508.365,510.382,514.506,516.524,519.789,523.525,525.542,528.365,530.771,533.648,535.665,539.401,541.418,543.4350000000001,546.279,549.156,551.948,558.091,562.216,566.34,568.746,572.87,576.606,578.624,584.766,586.783" y="189.697" svg_rhmargin="590.048" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">primary pterygium excision; a randomized clinical trial. J Ophthalmic</text>
  <text x="361.588,366.953,368.97,371.84700000000004,374.4,379.765,383.03,385.907,388.403,392.527,396.652,400.776,404.9,406.918,411.042,413.06,417.184" y="198.654" svg_rhmargin="421.308" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Vis Res 2014;9:22</text>
  <text x="421.342" y="198.654" svg_rhmargin="425.078" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="425.084,429.209,433.334" y="198.654" svg_rhmargin="435.351" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">30.</text>
  <text x="349.342,351.748,355.873,358.279,361.587,366.1,369.836,373.96,375.978,378.384,382.12,384.603,387.868,394.01,396.027,398.661,406.134,408.151,410.793,416.159,419.895,423.16,426.425,430.161,434.285,436.303,440.427,443.692,445.71,449.446,453.571,456.258,463.73,469.094,471.111,473.718,479.942,484.066,486.943,489.82,493.162,495.179,499.304,501.32099999999997,503.933,510.157,512.174,514.817,518.082,520.4879999999999,523.094,526.83,528.847,530.864,533.524,538.037,541.303,545.038,548.774,552.04,554.057,557.322,561.447,567.588,571.324,575.449,578.138,581.874,585.998" y="207.61199999999997" svg_rhmargin="590.122" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[7] Banifatemi M, Razeghinejad MR, Hosseini H, et al. Bevacizumab and</text>
  <text x="361.588,365.712,368.978,373.102,375.119,378.855,381.732,387.268,393.021,397.145,401.27,405.394,409.519,415.046,419.171,422.436,426.172,428.189,430.207,434.331,438.067,443.561,447.297,449.703,452.109,455.374,458.25100000000003,463.799,467.923,470.8,472.818,478.959,482.695,485.572,489.308,494.808,498.932,501.338,504.672,507.549,511.285,515.02,517.038,521.162,527.3040000000001,532.79,536.055,540.18,543.445,545.462,548.339,550.356,554.481,558.605,560.6220000000001,566.18,569.0569999999999,574.571,580.713,583.979,588.103" y="216.56899999999996" svg_rhmargin="590.12" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ocular wound healing after primary pterygium excision. J Ocul</text>
  <text x="361.588,365.712,369.837,373.573,376.449,382.591,386.327,389.592,393.787,395.804,398.265,403.168,407.292,410.625,413.502,415.953,420.078,424.202,428.327,432.451,434.469,438.593,442.717,444.807,448.932" y="225.52599999999995" svg_rhmargin="453.056" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Pharmacol Ther 2011;27:17</text>
  <text x="453.09" y="225.52599999999995" svg_rhmargin="456.826" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="456.775,460.9,465.025" y="225.52599999999995" svg_rhmargin="467.042" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">21.</text>
  <text x="349.342,351.748,355.873,358.279,361.587,365.712,369.447,373.572,377.696,380.634,384.37,386.388,389.65299999999996,394.92,400.674,402.691,408.015,413.769,417.893,421.629,425.753,427.771,433.913,435.93,441.235,447.46,449.477,454.784,459.298,462.175,464.192,467.928,474.07,476.087,481.372,486.738,488.755,494.071,497.336,499.742,505.013,508.749,510.766,512.783,518.109,521.844,525.969,530.093,532.97,535.376,537.782,540.188,543.453,546.33,552.4720000000001,557.791,560.667,563.933,566.809,570.934,572.951,575.357,578.2339999999999,583.584,587.709" y="234.48299999999995" svg_rhmargin="590.115" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[8] Fakhraie G, Ghadimi H, Eslami Y, et al. Short-term results of</text>
  <text x="361.588,363.994,366.871,370.606,374.731,377.996,381.261,385.386,387.494,390.759,394.024,396.43,400.555,406.697,410.433,412.891,417.015,419.892,421.909,426.034,429.77,432.222,435.958,440.082,442.099,446.224,450.419,453.684,456.09,458.107,461.843,465.108,467.595,469.613,473.737,476.143,479.02,482.756,486.021,489.757,495.899,499.164,502.04,505.776,507.793,510.281,514.406,517.671,521.407,525.143,528.408,530.425,533.69,537.888,544.03,547.766,551.89,553.907,556.369,560.105,562.548,565.425,569.161,573.285,577.409,581.534,587.676" y="243.44000000000005" svg_rhmargin="590.082" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">trabeculectomy using adjunctive intracameral bevacizumab: a random-</text>
  <text x="361.588,363.605,366.871,370.136,374.261,376.781,380.046,384.171,388.295,390.701,393.578,397.702,399.796,401.814,405.079,409.204,411.701,414.107,416.984,419.001,422.737,424.755,426.772,429.275,432.152,434.661,440.415,442.432,446.168,450.292,453.558,457.682,463.824,467.56,470.092,474.216,478.341,482.465,486.59,488.607,492.731,496.856,498.946,502.211,506.335,510.46" y="252.45399999999995" svg_rhmargin="514.584" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ized controlled trial. J Glaucoma 2016;25:e182</text>
  <text x="514.601" y="252.45399999999995" svg_rhmargin="518.337" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="518.343,522.468" y="252.45399999999995" svg_rhmargin="524.485" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text x="349.342,351.748,355.873,358.279,361.587,367.811,373.564,377.3,381.425,385.161,390.669,394.405,396.42199999999997,401.894,407.259,411.383,415.507,417.524,422.982,426.718,428.735,434.207,439.572,443.696,449.838,453.962,457.698,460.575,464.311,466.803,468.82,472.556,475.82099999999997,481.259,484.136,486.542,490.666,494.791,498.527,504.048,508.173,510.579,516.01,518.416,522.54,526.665,528.682,531.947,535.683,537.7,543.221,549.362,551.38,553.786,557.91,564.052,567.788,571.053,573.071,577.196,582.733,588.098" y="261.41200000000003" svg_rhmargin="590.115" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[9] Hwang S, Choi S. Comparative study of topical mitomycin C,</text>
  <text x="361.588,364.853,368.589,371.854,373.872,377.996,380.873,384.997,389.195,392.071,394.089,398.213,401.478,403.495,405.124,408.86,412.984,417.109,418.729,422.854,426.119,429.855,433.591,436.856,438.873,442.138,446.263,452.405,456.14,460.265,461.925,465.661,468.067,470.473,473.738,476.615,478.195,482.319,485.196,487.213,493.355,497.091,499.968,503.704,505.349,509.473,511.879,515.213,518.09,521.826,525.562,527.579,531.704,537.846,539.477,542.353,546.478,549.354,553.09,556.355,559.232,562.968,564.985,566.574,571.939,576.063,578.94,582.277,586.012" y="270.369" svg_rhmargin="590.136" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cyclosporine, and bevacizumab after primary pterygium surgery. Korean</text>
  <text x="361.588,364.46500000000003,366.974,373.115,377.24,381.364,383.77,387.895,391.631,393.648,399.79,403.914,405.931,408.469,412.593,416.718,420.842,424.967,427.063,431.188,435.312,437.329,441.454,445.578" y="279.326" svg_rhmargin="449.702" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">J Ophthalmol 2015;29:375</text>
  <text x="449.688" y="279.326" svg_rhmargin="453.424" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="453.43,457.555,461.68" y="279.326" svg_rhmargin="463.697" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">81.</text>
  <text x="345.204,347.61,351.734,355.859,358.265,361.587,366.952,370.688,373.564,377.3,379.318,382.583,385.848,387.866,389.883,395.26,400.625,402.642,408.015,413.38,417.505,420.77,424.894,429.019,432.284,435.16,439.285,443.409,447.534,453.763,457.028,460.293,465.612,470.976,472.993,478.31,483.675,487.799,491.924,495.66,499.396,504.784,510.149,515.514,517.5310000000001,522.868,526.133,528.539,533.866,537.602,539.619,541.6360000000001,547.018,552.771,556.896,560.161,563.0379999999999,568.389,570.795,574.92,579.044,581.062,584.327,588.063" y="288.283" svg_rhmargin="590.08" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[10] Karalezli A, Kucukerdonmez C, Akova YA, et al. Does topical</text>
  <text x="361.588,365.712,368.978,372.713,376.449,379.715,381.732,384.997,389.195,395.337,399.072,403.197,405.861,409.986,412.862,416.128,419.863,423.129,427.253,429.659,432.335,436.46,440.584,443.461,445.867,449.991,454.116,457.381,460.339,464.075,466.481,468.498,472.234,475.49899999999997,478.139,481.016,484.281,487.546,491.744,494.621,497.498,500.763,504.887,508.152,511.417,514.08,517.816,520.222,522.628,525.893,528.77,531.483,535.608,538.013,541.279,544.155,547.891,551.627,553.645,557.769,563.9110000000001,566.574,569.45,573.575,576.452,580.187,583.524,586.4" y="297.24" svg_rhmargin="590.136" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab prevent postoperative recurrence after pterygium surgery</text>
  <text x="361.588,367.341,369.359,371.765,375.89,378.425,381.69,385.814,389.939,391.956,396.081,400.205,403.47,405.876,407.894,411.63,415.365,417.382,419.92,423.656,427.781,430.186,434.376,438.112,440.988,444.724,447.13,449.536,451.554,455.678,459.414,462.679,465.214,467.62,471.745,474.151,476.665,479.54200000000003,482.051,488.193,492.317,496.442,498.848,502.972,506.708,508.725,514.867,518.992,521.009,523.547,527.671,531.795,535.92,540.044,542.062,546.186,548.204,552.328,556.453" y="306.254" svg_rhmargin="560.577" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">with conjunctival autografting? Int J Ophthalmol 2014;7:512</text>
  <text x="560.636" y="306.254" svg_rhmargin="564.372" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="564.378,568.503" y="306.254" svg_rhmargin="570.52" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">6.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,366.953,370.689,373.565,376.83,379.236,382.113,386.237,392.086,395.822,399.947,402.291,408.433,410.45,412.836,418.201,421.466,423.484,427.608,431.732,434.609,438.345,442.081,446.205,450.33,454.455,456.826,462.192,464.209,466.578,470.314,474.05,476.456,478.473,480.879,485.003,487.021,489.427,493.163,497.287,501.411,503.428,505.862,511.227,513.244,515.613,519.737,522.614,525.879,529.615,532.88,537.005,539.411,541.428,545.553,549.678,552.12,556.245,558.651,561.021,563.897,567.163,570.428,574.552,577.429,580.306,583.571,587.695" y="315.212" svg_rhmargin="590.101" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[11] Kasetsuwan N, Reinprayoon U, Satitpitakul V. Prevention of recurrent</text>
  <text x="361.589,365.713,368.119,371.384,374.261,377.997,381.733,383.75,387.875,394.017,397.133,402.887,404.904,407.31,411.435,414.538,416.944,421.068,425.192,427.21,430.475,434.211,436.228,439.31,443.435,446.7,450.436,454.172,457.437,459.454,462.719,466.917,473.059,476.795,480.92,483.98,488.105,490.122,494.247,498.371,505.84299999999996,508.923,512.189,515.925,519.1899999999999,522.246,526.37,529.247,533.371,537.496,540.372,542.389,545.488,549.224,552.291,555.168,558.904,563.028,567.153,571.277,577.419,579.437,582.702,585.967" y="324.169" svg_rhmargin="590.091" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">pterygium with topical bevacizumab 0.05% eye drops: a randomized</text>
  <text x="361.589,364.854,368.978,373.103,375.509,378.385,382.51,384.604,386.621,389.887,394.012,396.509,398.915,401.791,403.809,407.545,409.562,411.579,414.083,419.447,421.465,423.482,427.607,430.126,435.028,439.152,442.484,445.361,447.813,451.938,456.062,460.187,464.311,466.328,470.453,474.577,476.667,480.792,484.916,489.04" y="333.126" svg_rhmargin="493.164" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">controlled trial. Clin Ther 2015;37:2347</text>
  <text x="493.172" y="333.126" svg_rhmargin="496.908" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="496.914,501.039,505.165" y="333.126" svg_rhmargin="507.182" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">51.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,366.953,368.97,373.095,377.219,380.484,383.74899999999997,388.799,396.271,398.288,403.368,409.51,412.386,416.122,420.247,422.264,425.141,427.158,430.894,434.63,438.754,442.879,444.896,449.966,454.48,456.497,461.531,466.897,468.914,471.32,473.726,475.744,479.479,483.604,487.728,491.853,495.977,499.713,501.73,504.607,508.343,512.4680000000001,517.54,522.905,524.922,529.955,533.22,535.626,540.67,544.406,546.423,548.44,553.482,557.995" y="342.083" svg_rhmargin="560.401" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[12] Kiddee W, Orapiriyakul L, Kittigoonpaisan K, et al. Ef</text>
  <text x="560.41" y="342.083" svg_rhmargin="564.534" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="564.548,567.813,571.549,574.815,578.551,583.596,587.721" y="342.083" svg_rhmargin="590.127" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cacy of</text>
  <text x="361.589,365.325,369.449,371.466,375.591,379.715,382.98,385.386,387.495,391.231,394.496,397.813,400.689,404.814,408.938,412.203,416.328,420.452,422.47,426.594,430.718,433.984,436.474,438.491,442.227,445.963,447.98,451.326,455.451,458.716,462.452,466.188,469.453,471.47,474.736,478.86,485.002,488.738,492.863,496.224,500.348,504.473,507.845,510.251,514.376,517.641,520.997,525.122,529.246,531.652,534.917,539.042,545.184,548.449,551.3259999999999,554.727,558.852,561.2579999999999,564.592,568.716,571.593,573.61,579.752,583.488,586.365" y="351.04" svg_rhmargin="590.101" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">adjunctive subconjunctival bevacizumab on the outcomes of primary</text>
  <text x="361.589,363.995,366.871,370.607,374.732,377.997,381.262,385.386,387.495,390.76,394.025,396.431,400.556,406.697,410.433,413.175,418.928,420.945,423.351,427.476,430.238,436.38,438.397,440.803,444.928,451.069,454.805,458.07,460.088,464.213,466.972,472.337,474.354,477.12,480.856,483.583,487.707,490.584,494.708,497.585,501.71,504.975,508.24,510.646,512.663,516.399,519.664,522.415,525.291,529.027,533.152,537.276,541.462,547.604,549.622,552.887,556.152,560.277,563.005,567.129,569.146,572.882,576.148,579.413,583.537,587.662" y="359.998" svg_rhmargin="590.068" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">trabeculectomy with mitomycin C: a prospective randomized placebo-</text>
  <text x="361.589,364.854,368.978,373.103,375.509,378.385,382.51,384.604,386.621,389.887,394.012,396.509,398.915,401.791,403.809,407.545,409.562,411.579,414.083,416.96000000000004,419.468,425.222,427.24,430.976,435.1,438.365,442.49,448.72,452.456,454.9,459.025,463.149,467.274,471.398,473.415,477.54,481.664,483.754,487.879,492.004" y="369.012" svg_rhmargin="496.128" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">controlled trial. J Glaucoma 2015;24:600</text>
  <text x="496.12" y="369.012" svg_rhmargin="499.856" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="499.862,503.986" y="369.012" svg_rhmargin="506.003" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">6.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,366.101,369.366,373.491,377.615,381.351,385.475,389.6,393.787,396.193,400.93,406.295,408.312,413.006,417.13,420.866,423.272,427.008,429.956,433.691,437.816,439.833,442.239,444.645,448.381,454.52299999999997,459.264,464.165,466.182,470.942,475.844,479.968,484.092,488.217,491.953,496.077,500.202,502.219,505.484,511.23699999999997,516.01,520.134,522.1510000000001,526.838,530.103,532.5089999999999,537.269,541.005,543.023,545.0400000000001,549.798,555.163,558.899,563.023,567.148,571.272,577.414,579.431,582.696,585.962" y="377.969" svg_rhmargin="590.086" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[13] Lekhanont K, Patarakittam T, Thongphiew P, et al. Randomized</text>
  <text x="361.589,364.854,368.978,373.103,375.509,378.385,382.51,384.604,386.621,389.887,394.012,396.509,398.915,401.791,403.809,407.545,409.562,412.098,416.223,418.629,421.112,423.989,428.113,432.238,435.503,439.627,443.752,445.769,449.893,454.018,457.283,459.689,461.706,465.442,469.178,471.195,473.775,477.899,481.164,484.9,488.636,491.901,493.919,497.184,501.308,507.45,511.186,515.3109999999999,517.822,519.839,523.964,525.981,529.246,532.511,534.917,536.935,541.059,545.184,547.753,549.771,553.896,556.37,558.388,564.53,568.729,571.994,576.118,580.243,582.26,586.385" y="386.926" svg_rhmargin="590.121" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">controlled trial of subconjunctival bevacizumab injection in impending</text>
  <text x="361.589,364.465,367.731,370.996,375.12,377.997,380.873,384.139,388.345,390.75100000000003,393.221,397.345,399.751,403.016,405.893,409.629,413.365,415.382,419.506,425.648,427.665,430.238,433.974,436.474,440.598,442.616,444.633,448.758,451.164,453.651,456.528,458.934,463.058,467.256,470.992,473.009,475.476,480.842,484.966,487.843,491.967,495.232,498.968,501.497,505.621,509.745,513.87,517.994,520.012,524.136,528.261,530.35,534.475,538.599" y="395.883" svg_rhmargin="542.723" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">recurrent pterygium: a pilot study. Cornea 2012;31:155</text>
  <text x="542.722" y="395.883" svg_rhmargin="546.458" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="546.464,550.588,554.712" y="395.883" svg_rhmargin="556.729" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">61.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,366.101,368.118,372.243,375.364,380.728,386.87,388.887,391.974,397.338,401.463,405.199,409.324,412.381,418.135,421.012,423.029,426.101,431.466,435.59,438.855,443.051,446.787,449.854,455.607,459.343,461.36,464.423,467.688,470.094,473.153,476.889,478.906,480.923,484.037,489.402,491.419,493.437,497.561,499.579,502.844,506.58,508.597,511.701,514.578,517.843,520.719,523.985,527.72,530.597,533.862,537.987,541.123,545.247,547.6529999999999,550.703,552.72,556.845,559.251,562.128,565.863,567.881,571.146,574.023,576.04,580.164,584.289,588.117" y="404.84" svg_rhmargin="590.134" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[14] Lin YN, Zhao XJ, Zheng XS, et al. Clinical research of intralesional</text>
  <text x="361.589,365.713,368.978,372.714,376.45,379.715,381.733,384.998,389.195,395.337,399.073,403.198,405.069,407.086,411.21,413.228,416.493,419.758,422.164,424.181,428.306,432.431,434.32,438.444,442.569,444.411,448.535,451.412,453.429,459.571,463.307,466.183,469.919,471.791,475.915,478.321,481.655,484.532,488.268,492.004,494.021,498.145,504.287,506.304,508.185,512.31,514.138,517.403,521.528,523.5450000000001,525.419,530.784,534.909,536.926,541.051,544.787,546.8040000000001,548.662,551.068,555.193,557.599,560.864,563.74,567.865,571.678,574.084,576.101,580.226,584.35,588.086" y="413.797" svg_rhmargin="590.103" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab injection on primary pterygium. 3 ed. China: International</text>
  <text x="361.589,364.465,368.59,372.714,375.591,379.715,383.451,385.468,388.005,392.13,394.536,397.019,403.161,407.285,411.475,413.881,418.005,421.741,423.759,429.9,434.025,436.042,440.167,443.902,447.638,450.193,452.599,455.864,457.881,462.006,464.479,468.992,473.116,475.134,477.54,481.664,484.541,486.644,490.38,492.397,494.864,501.006" y="422.811" svg_rhmargin="503.412" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Journal of Ophthalmology (c/o Editorial Of</text>
  <text x="503.49" y="422.811" svg_rhmargin="507.614" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="507.572,510.837,514.102,516.508,518.5250000000001,521.064,525.188,529.313,533.437,537.562,539.579,543.703,547.828" y="422.811" svg_rhmargin="551.952" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ce), 2015;555</text>
  <text x="552.019" y="422.811" svg_rhmargin="555.755" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="555.761,559.885,564.01,568.134" y="422.811" svg_rhmargin="570.151" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">557.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,367.73,371.466,375.202,378.938,381.343,386.708,390.444,393.321,395.828,399.563,403.688,406.953,411.077,414.813,419.58,424.945,426.962,431.769,437.911,439.928,443.664,446.929,449.806,453.542,456.031,463.503,467.628,470.504,474.24,476.258,479.523,482.40000000000003,487.211,493.352,495.36899999999997,500.193,505.558,509.293,515.435,519.56,522.436,524.842,530.207,533.943,536.82,539.226,542.595,544.613,546.63,550.755,554.88,559.659,565.024,567.041,571.848,575.113,577.519,582.336,586.072,588.089" y="431.769" svg_rhmargin="590.106" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[15] Nava-Castaneda A, Olvera-Morales O, Ramos-Castellon C, et al.</text>
  <text x="361.589,366.954,370.689,374.814,378.938,383.131,389.273,391.291,394.556,397.821,401.945,403.962,405.41,408.675,412.8,416.924,419.33,422.207,426.331,428.348,430.366,433.631,437.756,439.253,441.659,444.535,446.553,450.289,452.306,453.765,457.89,460.296,461.759,465.024,469.148,473.273,475.29,479.414,483.539,486.804,489.21,491.227,494.963,498.699,500.716,502.177,505.913,510.038,512.443,516.633,520.369,523.245,526.981,529.387,531.793,533.811,537.935,541.6709999999999,543.106,546.372,550.496,556.638,560.762,562.78,566.904,570.26,574.385,575.816,581.57,583.588,585.994" y="440.726" svg_rhmargin="590.118" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Randomized, controlled trial of conjunctival autografting combined with</text>
  <text x="361.589,364.465,368.59,372.714,375.979,380.104,384.228,386.246,390.443,394.568,397.833,400.239,402.256,405.992,409.728,411.745,414.479,418.604,421.869,425.605,429.341,432.676,434.693,437.959,442.083,448.225,451.961,456.086,458.866,461.272,465.397,468.274,470.998,475.123,477.999,480.017,486.158,489.894,492.771,496.507,499.286,503.41,505.816,509.081,511.958,515.694,519.43,521.447,525.571,531.7130000000001,534.489,536.895,539.772,543.037,546.773,549.179,555.32,558.586,562.71,565.214,567.2310000000001,569.977,574.101,576.507,580.243,583.508,587.244" y="449.683" svg_rhmargin="590.121" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">subconjunctival bevacizumab for primary pterygium treatment: 1-year</text>
  <text x="361.589,363.995,368.119,370.137,372.154,376.278,382.032,384.438,388.562,392.686,394.703,397.302,402.667,404.685,406.702,410.827,413.346,417.859,421.983,426.108,429.373,432.25,434.267,440.409,443.674,447.798,450.204,452.744,458.886,463.01,467.135,469.54,473.665,477.401,479.418,485.56,489.684,491.701,494.239,498.364,502.488,506.613,510.737,512.754,516.879,518.896,523.094,527.218" y="458.64" svg_rhmargin="531.342" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">follow-up. Clin Experiment Ophthalmol 2014;3:235</text>
  <text x="531.383" y="458.64" svg_rhmargin="535.119" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="535.125,539.25,543.375" y="458.64" svg_rhmargin="545.392" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">41.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,367.73,370.995,374.731,378.855,381.732,385.856,389.592,393.717,395.26,399.773,404.286,406.303,407.788,413.153,416.889,420.154,423.89,425.419,430.784,432.801,434.262,439.627,443.363,446.24,449.976,451.496,457.638,459.655,461.133,464.398,466.80400000000003,468.276,472.012,474.03,476.04699999999997,477.573,482.475,486.599,490.724,492.741,496.006,499.742,501.759,503.253,506.989,511.114,515.238,517.255,519.273,522.538,526.274,528.763,530.78,534.905,539.03,540.497,544.622,547.0279999999999,548.547,552.672,555.937,559.673,563.409,566.674,568.692,571.957,576.081,582.223,585.959" y="467.597" svg_rhmargin="590.083" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[16] Ozgurhan EB, Agca A, Kara N, et al. Topical application of bevacizumab</text>
  <text x="361.589,365.325,368.202,370.716,374.451,378.576,381.09,384.826,388.95,390.968,395.092,399.217,402.482,404.88800000000003,407.394,409.8,413.925,416.465,419.341,422.606,425.872,429.996,432.873,435.749,439.014,443.139,445.545,448.04,452.164,454.57,457.903,460.78,464.516,468.252,470.269,474.393,480.53499999999997,483.017,485.893,490.018,492.894,496.63,499.966,502.843,506.579,508.596,511.078,516.442,520.567,523.443,527.568,530.833,534.569,537.097,541.222,545.346,549.471,553.595,555.613,559.737,563.862,565.951,570.076,574.2" y="476.555" svg_rhmargin="578.324" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">as an adjunct to recurrent pterygium surgery. Cornea 2013;32:835</text>
  <text x="578.325" y="476.555" svg_rhmargin="582.061" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="582.067,586.191" y="476.555" svg_rhmargin="588.208" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text x="345.205,347.61,351.735,355.859,358.265,361.588,367.73,370.995,373.872,377.996,380.402,383.753,387.878,389.252,396.725,398.742,400.137,405.503,409.239,411.256,415.38,417.786,421.522,425.647,427.065,431.578,433.59499999999997,435.001,440.366,444.49,448.615,452.351,456.476,457.904,460.78,466.145,468.162,469.582,472.847,475.253,476.668,480.404,482.421,484.438,485.851,491.216,494.481,498.606,501.871,505.607,508.013,511.278,515.403,516.86,520.984,524.25,527.986,531.721,534.987,537.004,540.269,544.394,550.536,554.271,558.396,559.83,561.847,565.972,567.989,571.254,574.519,576.925,578.943,583.067,587.192" y="485.569" svg_rhmargin="590.069" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[17] Ozsutcu M, Ayintap E, Akkan JC, et al. Repeated bevacizumab injections</text>
  <text svg_rhmargin="514.434" x="361.589,365.325,368.59,371.466,374.343,378.467,381.344,384.774,390.916,392.934,395.34,399.464,405.606,409.342,412.607,414.624,418.749,422.189,427.55400000000003,430.976,432.994,437.119,440.501,443.377,447.502,449.908,453.643,456.049,458.067,462.191,466.316,470.051,472.068,475.477,478.742,482.866,486.991,489.008,493.133,497.257,500.522,502.928,504.945,508.681,512.417,514.4340000000001" y="494.526" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">versus mitomycin C in rotational conjunctival </text>
  <text x="517.89" y="494.526" svg_rhmargin="522.014" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬂ</text>
  <text x="522.028,525.764,529.889,533.31,535.716,539.84,542.717,546.122,550.246,553.123,556.388,560.124,563.389,567.514,569.92,571.937,576.062,580.187,583.593,587.718" y="494.526" svg_rhmargin="590.124" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ap for prevention of</text>
  <text x="361.589,365.713,368.119,371.384,374.261,377.997,381.733,383.75,387.874,394.016,396.566,399.442,402.707,405.973,410.097,412.974,415.85,419.116,423.322,426.587,429.852,431.86899999999997,434.377,436.783,440.907,445.031,447.049,450.785,454.91,457.392,460.269,462.778,468.919,473.044,477.168,479.574,483.699,487.435,489.534,495.676,499.8,501.817,504.33,508.455,512.579,516.704,520.828,522.846,526.97,531.095,533.112,537.236,541.361" y="503.483" svg_rhmargin="545.485" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">pterygium recurrence. Indian J Ophthalmol 2014;62:407</text>
  <text x="545.556" y="503.483" svg_rhmargin="549.292" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="549.298,553.423,557.549" y="503.483" svg_rhmargin="559.566" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">11.</text>
  <text x="345.205,347.611,351.736,355.86,358.266,361.589,366.953,370.689,373.954,377.22,380.956,385.08,387.097,391.222,394.581,396.598,400.334,404.459,407.053,414.525,419.89,421.907,424.456,430.68,434.805,437.681,440.558,443.9,445.918,450.042,452.05899999999997,454.615,460.839,462.856,465.443,470.808,474.932,481.146,484.881,489.006,491.02299999999997,493.617,497.742,499.759,502.292,505.557,507.963,510.568,514.304,516.321,518.3380000000001,520.942,525.066,527.943,531.208,533.226,535.243,541.385,543.402,547.527,551.263,554.139,557.875,560.51,563.387,566.652,569.529,573.653,575.671,578.077,580.954,583.583,587.707" y="512.44" svg_rhmargin="590.113" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[18] Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of</text>
  <text x="361.589,364.466,368.59,372.715,375.98,380.104,384.229,386.246,390.444,394.568,397.834,400.239,402.257,405.993,409.729,411.746,414.366,418.491,421.756,425.492,429.228,432.493,434.51,437.776,441.9,448.042,451.778,455.903,458.526,460.544,464.669,467.313,471.437,474.314,476.331,482.473,486.209,489.086,492.822,495.431,499.555,501.961,505.226,508.103,511.839,515.575,517.592,521.717,527.859,530.521,533.787,537.911,541.176,543.194,546.07,548.088,552.212,556.337,558.354,561.02,567.162,571.286,575.411,577.817,581.941,585.677,587.694" y="521.3969999999999" svg_rhmargin="590.1" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">subconjunctival bevacizumab in primary pterygium excision. Ophthal-</text>
  <text x="361.589,367.731,369.749,373.014,375.535,380.9,384.165,387.04200000000003,389.594,393.719,397.843,401.968,406.092,408.11,412.234,416.358,418.376,422.5,426.625" y="530.354" svg_rhmargin="430.749" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">mic Res 2010;43:134</text>
  <text x="430.754" y="530.354" svg_rhmargin="434.49" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="434.496,438.621" y="530.354" svg_rhmargin="440.638" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text x="345.205,347.611,351.736,355.86,358.266,361.589,365.325,369.06,372.326,375.591,379.716,382.847,388.212,395.684,397.701,400.761,406.126,410.25,414.375,418.499,420.516,426.658,430.394,433.357,436.23400000000004,439.253,444.155,449.118,451.135,454.163,457.899,462.024,466.148,469.413,473.607,477.732,479.749,483.873,487.998,491.263,493.669,495.686,499.422,503.158,505.175,508.3,512.425,515.69,519.426,523.162,526.427,528.444,531.709,535.834,541.976,545.712,549.837,552.971,555.376,559.501,562.552,566.288,570.412,574.148,580.29,583.555,587.679" y="539.3679999999999" svg_rhmargin="590.085" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[19] Saeed AM, AboulNasr TT. Subconjunctival bevacizumab to augment</text>
  <text x="361.589,363.995,366.872,370.608,374.732,377.997,381.263,385.387,387.496,390.761,394.026,396.432,400.556,406.698,410.43399999999997,412.042,417.795,419.813,422.219,426.344,427.915,434.057,436.074,438.48,442.605,448.746,452.482,455.747,457.765,461.89,463.515,468.88,470.489,472.506,476.631,478.199,480.605,484.729,487.99399999999997,489.593,495.735,499.471,503.595,507.331,511.067,514.332,520.474,523.739,527.864,530.27,531.939,536.063,538.4689999999999,540.046,542.452,546.188,548.205,550.222,553.488,557.613,559.207,562.943,564.96,568.696,572.82,576.085,580.21,586.352" y="548.326" svg_rhmargin="590.088" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">trabeculectomy with mitomycin C in the management of failed glaucoma</text>
  <text x="361.589,364.466,368.59,371.467,375.203,378.468,381.345,385.081,387.098,389.65,395.014,397.032,399.049,403.174,405.693,411.835,415.959,420.084,422.49,426.614,430.35,432.367,438.509,442.634,444.651,447.189,451.313,455.437,459.562,463.686,465.704,469.828,471.845,476.043,480.167,484.292" y="557.283" svg_rhmargin="488.416" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">surgery. Clin Ophthalmol 2014;8:1745</text>
  <text x="488.411" y="557.283" svg_rhmargin="492.147" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="492.152,496.278,500.403" y="557.283" svg_rhmargin="502.42" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">55.</text>
  <text x="345.205,347.611,351.736,355.86,358.266,361.589,365.325,368.59,372.714,376.45,380.636,382.653,386.778,390.902,395.026,397.903,401.214,408.686,414.05,416.067,419.355,426.826,430.951,433.827,436.233,439.969,442.375,446.111,449.455,451.472,454.728,460.093,462.11,465.443,470.345,474.081,477.817,481.941,485.677,489.413,491.43,494.752,500.116,502.133,505.41,509.922,514.047,519.865,522.271,526.396,530.52,533.397,536.662,539.933,542.81,546.934,551.059,554.389,558.513,562.638,564.655,568.78,572.904,576.169,578.575,580.593,584.328,588.064" y="566.24" svg_rhmargin="590.081" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[20] Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival</text>
  <text x="361.589,365.714,368.979,372.715,376.451,379.716,381.733,384.999,389.196,395.338,399.074,403.199,405.92,408.325,412.45,415.16,418.896,423.02,426.756,432.898,436.163,440.288,442.694,445.431,447.837,450.714,454.45,458.574,461.839,465.104,469.229,471.246,474.511,477.776,480.182,484.307,490.449,494.185,496.96,499.366,503.491,506.368,509.092,512.828,514.846,518.581,522.706,525.971,530.096,536.237,539.973,541.99,544.749,550.115,552.132,554.15,558.275,561.02,567.162,571.286,575.411,577.817,581.941,585.677,587.694" y="575.197" svg_rhmargin="590.1" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthal-</text>
  <text x="361.589,367.731,371.856,373.873,376.385,380.509,384.634,388.758,392.883,394.9,399.025,401.042,405.24,409.364" y="584.154" svg_rhmargin="413.488" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">mol 2011;5:797</text>
  <text x="413.463" y="584.154" svg_rhmargin="417.199" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="417.205,421.33,425.455,429.581" y="584.154" svg_rhmargin="431.598" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">800.</text>
  <text x="345.205,347.611,351.736,355.86,358.266,361.589,365.325,369.449,373.185,377.309,379.327,383.452,384.888,392.36,399.832,401.849,403.255,407.768,409.785,413.91,417.175,421.299,425.424,429.16,432.036,435.772,437.211,442.576,450.048,452.065,453.481,457.994,460.012,465.765,469.501,473.626,475.023,482.495,489.967,491.984,493.39,495.796,499.921,502.327,505.203,508.939,513.064,517.188,520.453,523.33,527.066,529.472,531.489,535.225,538.49,539.931,542.807,546.932,551.056,554.387,558.511,562.635,564.653,568.777,572.902,576.167,578.573,580.59,584.326,588.062" y="593.112" svg_rhmargin="590.079" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[21] Shahin MM, Elbendary AM, Elwan MM. Intraoperative subconjunctival</text>
  <text x="361.589,365.714,368.979,372.715,376.451,379.716,381.733,384.999,389.196,395.338,399.074,403.199,408.074,411.81,414.687,419.525,423.261,427.386,432.28,436.016,440.14,442.158,446.282,450.407,453.672,456.078,458.095,461.831,465.096,470.034,472.44,475.317,478.582,482.318,484.724,490.866,494.131,498.255,500.661,505.578,507.595,511.72,516.576,520.701,523.577,525.595,531.736,535.472,538.349,542.085,547.018,551.142,553.548,556.813,559.69,563.426,567.162,569.179,573.304,579.445,581.4620000000001,586.416" y="602.126" svg_rhmargin="590.152" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab as an adjunctive treatment in primary pterygium: a</text>
  <text x="361.589,365.714,368.59,371.856,373.873,375.89,382.032,384.05,388.174,391.91,394.787,398.52299999999997,401.101,403.978,407.243,411.367,415.492,418.368,420.774,422.791,425.307,431.448,435.573,439.762,442.168,446.293,450.029,452.046,458.188,460.205,463.46999999999997,466.009,469.745,473.87,476.746,480.48199999999997,482.959,487.472,491.208,494.085,497.35,500.226,503.103,505.634,508.04,514.182,517.918,521.654,523.671,527.796,531.532,534.092,538.217,542.341,546.466,550.59,552.608,556.732,560.856,562.874,566.998,571.123" y="611.083" svg_rhmargin="575.247" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">preliminary report. Ophthalmic Surg Lasers Imaging 2012;43:459</text>
  <text x="575.32" y="611.083" svg_rhmargin="579.056" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="579.062,583.187,587.311" y="611.083" svg_rhmargin="589.328" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">66.</text>
  <text x="345.205,347.611,351.736,355.86,358.266,361.589,365.325,369.449,372.714,376.839,380.636,383.512,385.529,387.155,392.52,394.537,396.226,403.697,407.822,411.946,414.823,418.559,422.295,424.312,425.987,430.111,432.128,433.753,437.489,441.613,445.737,449.473,451.879,457.244,461.368,465.104,467.981,469.998,471.677,475.412,477.429,479.103,482.368,484.774,486.416,490.152,492.169,494.186,495.884,499.62,503.744,507.868,511.134,515.258,519.383,521.4,525.524,529.649,532.914,535.32,537.337,541.073,544.809,546.826,548.547,552.671,555.936,559.672,563.408,566.673,568.691,571.956,576.08,582.222,585.958" y="620.04" svg_rhmargin="590.082" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[22] Shenasi A, Mousavi F, Shoa-Ahari S, et al. Subconjunctival bevacizumab</text>
  <text svg_rhmargin="532.608" x="361.589,363.607,369.749,375.89,379.156,383.28,385.297,389.033,391.439,394.808,396.826,400.562,403.086,406.821,409.227,411.633,414.898,417.77500000000003,420.319,423.584,427.709,430.974,432.991,435.868,437.885,442.01,446.135,448.663,452.788,455.194,457.734,461.859,464.735,466.753,472.895,476.63,479.507,483.243,485.795,489.92,492.326,495.591,498.467,502.203,505.939,507.957,512.081,518.223,520.24,522.813,525.219,529.343,532.608" y="628.9970000000001" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">immediately after excision of primary pterygium: the </text>
  <text x="535.182" y="628.9970000000001" svg_rhmargin="539.306" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="539.321,542.198,545.074,547.4799999999999,549.979,553.244,555.262,557.279,561.403,563.421,566.686,570.422,572.4390000000001,575.035,577.441,580.318,582.335,586.071,588.088" y="628.9970000000001" svg_rhmargin="590.105" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">rst clinical trial.</text>
  <text x="361.59,366.955,371.079,373.956,378.08,381.346,385.082,387.61,391.734,395.859,399.983,404.108,406.125,410.249,414.374,416.464,420.588,424.713,428.837" y="637.954" svg_rhmargin="432.961" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Cornea 2011;30:1219</text>
  <text x="432.966" y="637.954" svg_rhmargin="436.702" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="436.705,440.831,444.956" y="637.972" svg_rhmargin="446.973" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">22.</text>
  <text x="345.204,347.609,351.735,355.859,358.265,361.588,365.324,367.143,371.268,374.797,378.922,379.956,384.082,386.099,387.043,390.779,394.315,397.192,401.116,404.852,407.729,408.656,413.169,415.186,416.139,419.875,422.94,425.346,429.27,431.287,432.331,438.556,442.083,444.1,445.144,448.409,450.815,451.777,455.513,457.33,459.347,460.391,466.797,469.674,473.21,477.334,481.258,485.383,491.324,493.342,496.407,499.672,503.797,504.74,508.005,511.883,516.008,518.213,521.09,525.014,527.031,528.812,532.077,536.202,537.145,541.27,543.946,548.071,550.747,554.871,557.936,561.202,563.407,565.425,568.96,572.225,573.269,576.145,578.371,582.496,586.421" y="646.929" svg_rhmargin="590.157" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[23] Singh P, Sarkar L, Sethi HS, et al. Arandomized controlled prospective study</text>
  <text x="361.588,363.994,368.119,370.772,374.508,377.178,379.899,383.164,385.852,388.729,391.464,393.732,397.857,401.122,403.767,406.643,410.57,412.587,415.852,418.45,422.574,424.98,427.576,430.453,434.379,438.505,441.58,445.705,449.631,451.502,455.626,459.552,462.817,465.05,467.068,470.606,474.342,476.359,478.94,483.064,486.139,489.875,493.396,496.661,498.441,501.706,505.641,511.783,515.335,519.46,522.138,524.155,528.28,530.925,535.049,537.728,539.745,545.664,549.4,552.071,555.807,558.534,562.658,564.827,568.092,570.779,574.515,578.035,580.053,583.988" y="655.943" svg_rhmargin="590.13" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">to assess the role of subconjunctival bevacizumab in primary pterygium</text>
  <text x="361.588,364.464,368.391,371.267,374.797,378.062,380.75,384.486,386.589,388.606,392.731,394.81,397.077,401.202,405.127,407.145,410.683,414.808,416.919,421.044,424.573,426.979,428.825,431.943,436.067,438.292,441.169,443.186,445.208,447.614,451.558,455.682,457.454,461.19,465.315,467.375,470.252,472.364,478.506,482.455,486.58,488.749,492.874,496.403,498.42,504.396,508.52,510.537,512.56,516.684,520.61,524.734,528.66,530.531,534.655,538.581,540.599,544.534,548.658" y="664.9" svg_rhmargin="552.782" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">surgery in Indian patients. Indian J Ophthalmol 2015;63:779</text>
  <text x="552.585" y="664.9" svg_rhmargin="556.321" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="556.213,560.338,564.263" y="664.9" svg_rhmargin="566.28" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">84.</text>
  <text x="345.204,347.609,351.734,355.858,358.264,361.587,366.488,370.224,372.241,377.346,382.248,387.613,389.63,394.694,402.165,406.29,409.167,411.572,414.838,417.71500000000003,422.755,430.227,435.591,437.608,442.709,446.833,449.71,453.835,458.866,466.339,469.215,471.23199999999997,476.327,479.592,481.998,487.041,490.777,492.795,494.812,499.91,506.052,509.317,512.582,516.707,518.724,521.989,527.064,531.189,533.206,536.471,540.596,545.658,548.535,551.8,555.536,557.554,560.43,562.448,566.572,570.697,575.76,581.513,583.531,585.937" y="673.857" svg_rhmargin="590.061" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[24] Tai TY, Moster MR, Pro MJ, et al. Needle bleb revision with</text>
  <text x="361.588,365.712,368.977,372.713,376.449,379.714,381.732,384.997,389.194,395.336,399.072,403.197,405.804,409.54,413.665,417.79,420.373,426.515,428.533,430.939,435.063,441.205,444.941,448.206,450.223,454.348,456.994,462.35900000000004,464.988,468.253,472.377,478.519,482.643,486.379,489.256,492.521,496.646,499.284,505.037,507.055,509.46,513.585,516.234,522.375,524.393,526.799,530.923,537.065,540.801,544.066,546.084,550.209,552.854,558.219,560.792,564.528,566.545,570.67,574.794,578.059,580.69,583.096,587.22" y="682.814" svg_rhmargin="590.097" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab and mitomycin C compared with mitomycin C alone for</text>
  <text svg_rhmargin="381.642" x="361.588,363.994,367.729,369.747,371.764,373.782,377.906,381.642" y="691.772" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">failing </text>
  <text x="384.208" y="691.772" svg_rhmargin="388.332" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="388.346,390.364,392.77,395.646,399.382,401.788,403.806,407.93,412.055,414.593,418.718,420.735,424.0,428.125,431.001,433.018,435.511,438.38800000000003,440.897,446.651,448.668,452.404,456.529,459.794,463.918,470.06,473.796,476.328,480.453,484.577,488.702,492.826,494.843,498.968,503.092,505.182,509.307,513.431" y="691.772" svg_rhmargin="517.555" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ltration blebs. J Glaucoma 2015;24:311</text>
  <text x="517.549" y="691.772" svg_rhmargin="521.285" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="521.291,525.416" y="691.772" svg_rhmargin="527.433" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5.</text>
  <text x="345.204,347.609,351.734,355.858,358.264,361.587,366.952,370.688,374.812,378.936,382.202,387.955,391.691,393.786,395.803,399.068,403.14,407.653,409.67,413.741,419.106,423.23,426.495,430.231,433.967,438.092,442.199,446.323,448.34,452.465,454.871,458.996,463.061,467.574,469.591,473.662,479.028,482.764,486.889,491.01,495.523,498.788,501.665,505.401,508.666,512.7909999999999,516.861,521.762,523.779,527.858,531.123,533.529,537.609,541.345,543.362,545.379,549.457,551.863,555.987,558.393,561.27,565.006,568.271,572.007,578.149,581.414,584.291,588.119" y="700.729" svg_rhmargin="590.136" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[25] Vandewalle E, Abegao Pinto L, Van Bergen T, et al. Intracameral</text>
  <text x="361.588,365.712,368.977,372.713,376.449,379.714,381.732,384.997,389.194,395.336,399.072,403.197,406.825,410.561,413.438,417.086,420.822,424.947,428.594,432.33,436.454,438.472,442.596,446.721,449.986,452.392,456.088,458.494,462.619,466.235,468.641,471.518,475.254,479.378,482.643,485.909,490.033,492.142,495.407,498.672,501.078,505.202,511.344,515.08,517.0970000000001,520.769,524.505,528.139,532.264,534.67,538.406,541.671,545.407,548.284,551.949,556.073,558.95,563.074,565.951,570.075,573.341,576.606,579.012,581.029,584.765,588.03" y="709.7429999999999" svg_rhmargin="590.047" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bevacizumab as an adjunct to trabeculectomy: a 1-year prospective,</text>
  <text x="361.588,364.464,368.2,372.325,376.449,380.635,386.777,388.794,391.671,394.936,399.061,401.553,404.429,406.835,410.96,415.084,418.82,420.837,423.378,427.891,430.76800000000003,433.242,436.119,438.628,444.77,448.895,453.019,455.425,459.55,463.286,465.385,471.527,475.651,477.668,480.181,484.305,488.43,492.554,496.678,498.696,502.82,506.945,508.962,513.086" y="718.7" svg_rhmargin="517.21" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">randomised study. Br J Ophthalmol 2014;98:73</text>
  <text x="517.266" y="718.7" svg_rhmargin="521.002" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="521.008,525.132" y="718.7" svg_rhmargin="527.149" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">8.</text>
  <text x="85.039,90.595,94.827,98.892,103.124,107.523,110.154,114.218,116.537,119.168,123.233,124.643,126.795,129.429,135.98,140.045,144.604,146.015,150.079,151.49,155.722,159.787,162.366,164.271,168.671,173.07,177.47,181.869,183.774,186.403,190.802,195.202,197.354,201.753,206.152,517.041,522.931,528.821,534.711,536.863,543.414,547.973,550.874,552.285,556.685,560.917,563.3,567.532,571.597,573.008,575.16,579.224,583.624" y="9.870999999999981" svg_rhmargin="590.176" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Huang et al. Medicine (2018) 97:34 www.md-journal.com</text>
  <text x="335.396" y="739.625" svg_rhmargin="339.796" style="fill:#171615;font-family:DPNDMJ+AdvOTf94803d4;font-size:7.97px;font-style:NORMAL;font-weight:normal;">9</text>
 </g>
</svg>
